NZ579417A - Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators - Google Patents

Info

Publication number

NZ579417A

NZ579417A NZ579417A NZ57941708A NZ579417A NZ 579417 A NZ579417 A NZ 579417A NZ 579417 A NZ579417 A NZ 579417A NZ 57941708 A NZ57941708 A NZ 57941708A NZ 579417 A NZ579417 A NZ 579417A

Authority

NZ

New Zealand

Prior art keywords

compound

oxo

phenoxy

iponz

december

Prior art date

2007-03-07

Links

• Espacenet
• Global Dossier
• Discuss

• QOGFHXOSRWCQBZ-UHFFFAOYSA-N 1-oxo-4-phenoxy-1,3-thiazol-2-amine Chemical class O=S1C(N)=NC(OC=2C=CC=CC=2)=C1 QOGFHXOSRWCQBZ-UHFFFAOYSA-N 0.000 title abstract 2
• 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 title description 59
• 108091008559 estrogen-related receptor alpha Proteins 0.000 title description 53
• 150000001875 compounds Chemical class 0.000 claims abstract description 209
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 66
• 201000010099 disease Diseases 0.000 claims abstract description 35
• 208000035475 disorder Diseases 0.000 claims abstract description 31
• 150000003839 salts Chemical class 0.000 claims abstract description 26
• 210000000988 bone and bone Anatomy 0.000 claims abstract description 22
• 206010003246 arthritis Diseases 0.000 claims abstract description 17
• 230000003287 optical effect Effects 0.000 claims abstract description 15
• 210000000845 cartilage Anatomy 0.000 claims abstract description 14
• 230000001684 chronic effect Effects 0.000 claims abstract description 14
• 208000002574 reactive arthritis Diseases 0.000 claims abstract description 14
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 13
• 239000008103 glucose Substances 0.000 claims abstract description 12
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 11
• 208000008589 Obesity Diseases 0.000 claims abstract description 10
• 208000001132 Osteoporosis Diseases 0.000 claims abstract description 10
• 230000002757 inflammatory effect Effects 0.000 claims abstract description 10
• 235000020824 obesity Nutrition 0.000 claims abstract description 10
• 208000023504 respiratory system disease Diseases 0.000 claims abstract description 10
• 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 9
• 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 9
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 9
• 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 9
• 210000004369 blood Anatomy 0.000 claims abstract description 8
• 239000008280 blood Substances 0.000 claims abstract description 8
• 230000019439 energy homeostasis Effects 0.000 claims abstract description 8
• 201000001421 hyperglycemia Diseases 0.000 claims abstract description 8
• 150000002632 lipids Chemical class 0.000 claims abstract description 8
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims abstract description 7
• 206010003267 Arthritis reactive Diseases 0.000 claims abstract description 7
• 208000025940 Back injury Diseases 0.000 claims abstract description 7
• 206010006458 Bronchitis chronic Diseases 0.000 claims abstract description 7
• 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 7
• 206010007710 Cartilage injury Diseases 0.000 claims abstract description 7
• 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims abstract description 7
• 208000005243 Chondrosarcoma Diseases 0.000 claims abstract description 7
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 7
• 208000012514 Cumulative Trauma disease Diseases 0.000 claims abstract description 7
• 201000005569 Gout Diseases 0.000 claims abstract description 7
• 208000004575 Infectious Arthritis Diseases 0.000 claims abstract description 7
• 206010027476 Metastases Diseases 0.000 claims abstract description 7
• 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 7
• 208000010191 Osteitis Deformans Diseases 0.000 claims abstract description 7
• 206010031243 Osteogenesis imperfecta Diseases 0.000 claims abstract description 7
• 208000027868 Paget disease Diseases 0.000 claims abstract description 7
• 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 7
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims abstract description 7
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims abstract description 7
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims abstract description 7
• 208000033464 Reiter syndrome Diseases 0.000 claims abstract description 7
• 206010006451 bronchitis Diseases 0.000 claims abstract description 7
• 230000022159 cartilage development Effects 0.000 claims abstract description 7
• 208000002849 chondrocalcinosis Diseases 0.000 claims abstract description 7
• 208000017568 chondrodysplasia Diseases 0.000 claims abstract description 7
• 208000007451 chronic bronchitis Diseases 0.000 claims abstract description 7
• 230000007850 degeneration Effects 0.000 claims abstract description 7
• 208000027202 mammary Paget disease Diseases 0.000 claims abstract description 7
• 230000009401 metastasis Effects 0.000 claims abstract description 7
• 230000011164 ossification Effects 0.000 claims abstract description 7
• 201000008482 osteoarthritis Diseases 0.000 claims abstract description 7
• 230000000010 osteolytic effect Effects 0.000 claims abstract description 7
• 208000005368 osteomalacia Diseases 0.000 claims abstract description 7
• 208000028169 periodontal disease Diseases 0.000 claims abstract description 7
• 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 7
• 201000001223 septic arthritis Diseases 0.000 claims abstract description 7
• 238000000034 method Methods 0.000 claims description 59
• 125000000623 heterocyclic group Chemical group 0.000 claims description 38
• 125000005843 halogen group Chemical group 0.000 claims description 34
• 239000005557 antagonist Substances 0.000 claims description 31
• 239000003795 chemical substances by application Substances 0.000 claims description 28
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 28
• 239000008194 pharmaceutical composition Substances 0.000 claims description 26
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
• 125000001072 heteroaryl group Chemical group 0.000 claims description 24
• 239000003814 drug Substances 0.000 claims description 23
• 125000000217 alkyl group Chemical group 0.000 claims description 21
• 125000003118 aryl group Chemical group 0.000 claims description 19
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
• 239000003112 inhibitor Substances 0.000 claims description 16
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
• 230000001404 mediated effect Effects 0.000 claims description 14
• 238000002360 preparation method Methods 0.000 claims description 13
• 206010006187 Breast cancer Diseases 0.000 claims description 12
• 208000026310 Breast neoplasm Diseases 0.000 claims description 12
• 229940125708 antidiabetic agent Drugs 0.000 claims description 12
• 239000003472 antidiabetic agent Substances 0.000 claims description 12
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
• 229940079593 drug Drugs 0.000 claims description 11
• 239000003937 drug carrier Substances 0.000 claims description 10
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
• 125000003545 alkoxy group Chemical group 0.000 claims description 9
• 125000004043 oxo group Chemical group O=* 0.000 claims description 9
• 229910052760 oxygen Inorganic materials 0.000 claims description 9
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
• AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 8
• UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims description 8
• 230000008569 process Effects 0.000 claims description 7
• 229960004425 sibutramine Drugs 0.000 claims description 7
• 229910052717 sulfur Inorganic materials 0.000 claims description 7
• 239000000883 anti-obesity agent Substances 0.000 claims description 6
• 229940125710 antiobesity agent Drugs 0.000 claims description 6
• 229960001243 orlistat Drugs 0.000 claims description 6
• 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 5
• 239000003524 antilipemic agent Substances 0.000 claims description 5
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
• 229940125425 inverse agonist Drugs 0.000 claims description 5
• 229940123900 Direct thrombin inhibitor Drugs 0.000 claims description 4
• 102000030595 Glucokinase Human genes 0.000 claims description 4
• 108010021582 Glucokinase Proteins 0.000 claims description 4
• 239000003868 thrombin inhibitor Substances 0.000 claims description 4
• 229940124802 CB1 antagonist Drugs 0.000 claims description 3
• 230000036772 blood pressure Effects 0.000 claims description 3
• 230000000407 monoamine reuptake Effects 0.000 claims description 3
• JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical group CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims description 3
• 229960003015 rimonabant Drugs 0.000 claims description 3
• 229940127470 Lipase Inhibitors Drugs 0.000 claims description 2
• 239000003146 anticoagulant agent Substances 0.000 claims description 2
• 229960004676 antithrombotic agent Drugs 0.000 claims description 2
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
• -1 optical isomers Chemical class 0.000 abstract description 107
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 8
• UJLLZGIBDWGYJF-UHFFFAOYSA-N 4-[4-[(2-amino-4-oxo-1,3-thiazol-5-ylidene)methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(N)=NC1=O UJLLZGIBDWGYJF-UHFFFAOYSA-N 0.000 abstract description 3
• 238000005160 1H NMR spectroscopy Methods 0.000 description 133
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 128
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 118
• 239000000556 agonist Substances 0.000 description 36
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 35
• 239000000203 mixture Substances 0.000 description 34
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
• 102000004877 Insulin Human genes 0.000 description 30
• 108090001061 Insulin Proteins 0.000 description 30
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 30
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 24
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
• 108090000623 proteins and genes Proteins 0.000 description 20
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 18
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 18
• NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 18
• 239000002904 solvent Substances 0.000 description 18
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 17
• 229940125396 insulin Drugs 0.000 description 17
• PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 17
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
• 230000000694 effects Effects 0.000 description 16
• 102000003797 Neuropeptides Human genes 0.000 description 15
• 108090000189 Neuropeptides Proteins 0.000 description 15
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
• PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 15
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
• AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 13
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 13
• 102000005962 receptors Human genes 0.000 description 13
• 108020003175 receptors Proteins 0.000 description 13
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 12
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 11
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 11
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 11
• 229940011871 estrogen Drugs 0.000 description 11
• 239000000262 estrogen Substances 0.000 description 11
• 230000002401 inhibitory effect Effects 0.000 description 11
• 239000003446 ligand Substances 0.000 description 11
• 108010029667 pramlintide Proteins 0.000 description 11
• 102000016267 Leptin Human genes 0.000 description 10
• 108010092277 Leptin Proteins 0.000 description 10
• 229940126033 PPAR agonist Drugs 0.000 description 10
• 239000012190 activator Substances 0.000 description 10
• 150000001299 aldehydes Chemical class 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 229910052799 carbon Inorganic materials 0.000 description 10
• 238000006243 chemical reaction Methods 0.000 description 10
• 239000002552 dosage form Substances 0.000 description 10
• 235000019439 ethyl acetate Nutrition 0.000 description 10
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
• 229940039781 leptin Drugs 0.000 description 10
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 10
• 239000007788 liquid Substances 0.000 description 10
• 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 10
• 125000001424 substituent group Chemical group 0.000 description 10
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 10
• AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 9
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
• 108020004017 nuclear receptors Proteins 0.000 description 9
• 229910000027 potassium carbonate Inorganic materials 0.000 description 9
• 102000004169 proteins and genes Human genes 0.000 description 9
• 239000003772 serotonin uptake inhibitor Substances 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 239000003826 tablet Substances 0.000 description 9
• TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 8
• 108010011459 Exenatide Proteins 0.000 description 8
• 238000006000 Knoevenagel condensation reaction Methods 0.000 description 8
• 102000023984 PPAR alpha Human genes 0.000 description 8
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
• 239000002253 acid Substances 0.000 description 8
• 229960002938 bexarotene Drugs 0.000 description 8
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 8
• 229910052757 nitrogen Inorganic materials 0.000 description 8
• 229940103453 novolin Drugs 0.000 description 8
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 208000024891 symptom Diseases 0.000 description 8
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
• WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 description 7
• AIRYAONNMGRCGJ-FHFVDXKLSA-N CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC AIRYAONNMGRCGJ-FHFVDXKLSA-N 0.000 description 7
• LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 7
• IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 7
• 108010028924 PPAR alpha Proteins 0.000 description 7
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
• 239000004480 active ingredient Substances 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 239000011541 reaction mixture Substances 0.000 description 7
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 7
• 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 7
• 229940076279 serotonin Drugs 0.000 description 7
• BLFQGGGGFNSJKA-XHXSRVRCSA-N sertraline hydrochloride Chemical compound Cl.C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 BLFQGGGGFNSJKA-XHXSRVRCSA-N 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 7
• 229960004380 tramadol Drugs 0.000 description 7
• TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 7
• QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 description 7
• HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 7
• GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 6
• CGTZMJIMMUNLQD-STYNFMPRSA-N (2r)-2-[(r)-(2-ethoxyphenoxy)-phenylmethyl]morpholine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CGTZMJIMMUNLQD-STYNFMPRSA-N 0.000 description 6
• HYMJHROUVPWYNQ-UHFFFAOYSA-N 2-amino-1,3-thiazol-4-one Chemical compound NC1=NC(=O)CS1 HYMJHROUVPWYNQ-UHFFFAOYSA-N 0.000 description 6
• 239000005711 Benzoic acid Substances 0.000 description 6
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
• 108010032363 ERRalpha estrogen-related receptor Proteins 0.000 description 6
• 229930006000 Sucrose Natural products 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 230000001833 anti-estrogenic effect Effects 0.000 description 6
• 235000010233 benzoic acid Nutrition 0.000 description 6
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 6
• LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 6
• 239000000328 estrogen antagonist Substances 0.000 description 6
• YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 6
• 230000014509 gene expression Effects 0.000 description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 229960003105 metformin Drugs 0.000 description 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
• DYCKFEBIOUQECE-UHFFFAOYSA-N nefazodone hydrochloride Chemical compound [H+].[Cl-].O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 DYCKFEBIOUQECE-UHFFFAOYSA-N 0.000 description 6
• 229960002296 paroxetine Drugs 0.000 description 6
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 6
• 108090000765 processed proteins & peptides Proteins 0.000 description 6
• 235000018102 proteins Nutrition 0.000 description 6
• 229920006395 saturated elastomer Polymers 0.000 description 6
• 239000005720 sucrose Substances 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
• XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 5
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 5
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 5
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
• DTPWZYSUQQHRKD-VIUAGAKSSA-N CC(O)=O.CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O Chemical compound CC(O)=O.CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O DTPWZYSUQQHRKD-VIUAGAKSSA-N 0.000 description 5
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
• 102000008169 Co-Repressor Proteins Human genes 0.000 description 5
• 108010060434 Co-Repressor Proteins Proteins 0.000 description 5
• 102000013266 Human Regular Insulin Human genes 0.000 description 5
• 108010090613 Human Regular Insulin Proteins 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 5
• 108010016731 PPAR gamma Proteins 0.000 description 5
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
• FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 5
• 150000001412 amines Chemical class 0.000 description 5
• 229940046836 anti-estrogen Drugs 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 5
• 210000004027 cell Anatomy 0.000 description 5
• 229960001653 citalopram Drugs 0.000 description 5
• 239000010779 crude oil Substances 0.000 description 5
• 235000014113 dietary fatty acids Nutrition 0.000 description 5
• 239000000194 fatty acid Substances 0.000 description 5
• 229930195729 fatty acid Natural products 0.000 description 5
• 150000004665 fatty acids Chemical class 0.000 description 5
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
• 229940103471 humulin Drugs 0.000 description 5
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 208000030159 metabolic disease Diseases 0.000 description 5
• OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 5
• 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 5
• 229960002748 norepinephrine Drugs 0.000 description 5
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
• 239000006187 pill Substances 0.000 description 5
• 229940002612 prodrug Drugs 0.000 description 5
• 239000000651 prodrug Substances 0.000 description 5
• 150000003254 radicals Chemical class 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 5
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 5
• 239000001632 sodium acetate Substances 0.000 description 5
• 235000017281 sodium acetate Nutrition 0.000 description 5
• 239000000375 suspending agent Substances 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 4
• ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 4
• ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 4
• WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 4
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
• HQDFNBIIRSAPNA-UHFFFAOYSA-N 4-[4-[[2-(3-fluoropyrrolidin-1-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCC(F)C1 HQDFNBIIRSAPNA-UHFFFAOYSA-N 0.000 description 4
• SLXTWXQUEZSSTJ-UHFFFAOYSA-N 6-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(C=2N=CC(=CC=2)C(O)=O)CC1 SLXTWXQUEZSSTJ-UHFFFAOYSA-N 0.000 description 4
• 239000005695 Ammonium acetate Substances 0.000 description 4
• WEDIKSVWBUKTRA-WTKGVUNUSA-N CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC WEDIKSVWBUKTRA-WTKGVUNUSA-N 0.000 description 4
• 229920002261 Corn starch Polymers 0.000 description 4
• HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 4
• 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 4
• 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 4
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
• 206010028980 Neoplasm Diseases 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 229940123464 Thiazolidinedione Drugs 0.000 description 4
• 102000040945 Transcription factor Human genes 0.000 description 4
• 108091023040 Transcription factor Proteins 0.000 description 4
• 235000010443 alginic acid Nutrition 0.000 description 4
• 229920000615 alginic acid Polymers 0.000 description 4
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
• 229910052782 aluminium Inorganic materials 0.000 description 4
• 150000001408 amides Chemical class 0.000 description 4
• 235000019257 ammonium acetate Nutrition 0.000 description 4
• 229940043376 ammonium acetate Drugs 0.000 description 4
• 239000000010 aprotic solvent Substances 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 229960001058 bupropion Drugs 0.000 description 4
• 201000011510 cancer Diseases 0.000 description 4
• 150000001721 carbon Chemical group 0.000 description 4
• 230000003197 catalytic effect Effects 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 229940098766 effexor Drugs 0.000 description 4
• 229960004341 escitalopram Drugs 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 4
• 229960004038 fluvoxamine Drugs 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 235000001727 glucose Nutrition 0.000 description 4
• 230000001965 increasing effect Effects 0.000 description 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
• MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 4
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 229960000600 milnacipran Drugs 0.000 description 4
• VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 4
• PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 4
• 239000002660 neuropeptide Y receptor antagonist Substances 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 239000003960 organic solvent Substances 0.000 description 4
• DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 230000000069 prophylactic effect Effects 0.000 description 4
• KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical compound O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 description 4
• SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 4
• 239000000952 serotonin receptor agonist Substances 0.000 description 4
• 239000012453 solvate Substances 0.000 description 4
• RPZBRGFNBNQSOP-UHFFFAOYSA-N vilazodone hydrochloride Chemical compound Cl.C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 RPZBRGFNBNQSOP-UHFFFAOYSA-N 0.000 description 4
• 238000005550 wet granulation Methods 0.000 description 4
• 229960004496 zotepine Drugs 0.000 description 4
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
• AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 3
• KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 3
• IMDIBCPOFHCAHY-UHFFFAOYSA-N 1-[5-[[3-methoxy-4-[2-(trifluoromethyl)phenoxy]phenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]azetidine-3-carboxylic acid Chemical compound C=1C=C(OC=2C(=CC=CC=2)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CC(C(O)=O)C1 IMDIBCPOFHCAHY-UHFFFAOYSA-N 0.000 description 3
• SOZGHDCEWOLLHV-UHFFFAOYSA-N 2-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=CC=C1C#N SOZGHDCEWOLLHV-UHFFFAOYSA-N 0.000 description 3
• LTBKOSQVBVYJKW-UHFFFAOYSA-N 4-(4-fluorophenyl)-1-[4-(1,2,4-triazol-1-yl)butyl]-3,6-dihydro-2h-pyridine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(F)=CC=C1C(CC1)=CCN1CCCCN1N=CN=C1 LTBKOSQVBVYJKW-UHFFFAOYSA-N 0.000 description 3
• VZDUUSJCPIKZRH-UHFFFAOYSA-N 4-(4-formyl-2-methoxyphenoxy)-3-(trifluoromethyl)benzonitrile Chemical compound COC1=CC(C=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F VZDUUSJCPIKZRH-UHFFFAOYSA-N 0.000 description 3
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
• XEDDRNQLJVHPLS-UHFFFAOYSA-N 4-[2-fluoro-4-[[4-oxo-2-[2-(1,2,4-triazol-1-yl)ethylamino]-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(F)=CC=1C=C(C(N=1)=O)SC=1NCCN1C=NC=N1 XEDDRNQLJVHPLS-UHFFFAOYSA-N 0.000 description 3
• IZTCRODQUZLQGM-UHFFFAOYSA-N 4-[2-methoxy-4-[(2-methylsulfanyl-4-oxo-1,3-thiazol-5-ylidene)methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(SC)=NC1=O IZTCRODQUZLQGM-UHFFFAOYSA-N 0.000 description 3
• AZKFGOQRYCSQPK-UHFFFAOYSA-N 5-[(7-phenylmethoxyquinolin-3-yl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CN=C(C=C(OCC=2C=CC=CC=2)C=C2)C2=C1 AZKFGOQRYCSQPK-UHFFFAOYSA-N 0.000 description 3
• IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 description 3
• HAAXAFNSRADSMK-UHFFFAOYSA-N 5-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=1C=CSC=11)=CC=C1CC1SC(=O)NC1=O HAAXAFNSRADSMK-UHFFFAOYSA-N 0.000 description 3
• ZLUWVRIZBDJIOF-UHFFFAOYSA-N 5-[[4-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenyl]methyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC(C=C1)=CC=C1CC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 ZLUWVRIZBDJIOF-UHFFFAOYSA-N 0.000 description 3
• JICJBGPOMZQUBB-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 description 3
• SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 3
• 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 3
• 229940123208 Biguanide Drugs 0.000 description 3
• 239000004215 Carbon black (E152) Substances 0.000 description 3
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 3
• GGUVRMBIEPYOKL-WMVCGJOFSA-N GW 409544 Chemical compound C([C@H](NC(/C)=C\C(=O)C=1C=CC=CC=1)C(O)=O)C(C=C1)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 GGUVRMBIEPYOKL-WMVCGJOFSA-N 0.000 description 3
• 208000002705 Glucose Intolerance Diseases 0.000 description 3
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 206010056997 Impaired fasting glucose Diseases 0.000 description 3
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
• 108010057186 Insulin Glargine Proteins 0.000 description 3
• 108010065920 Insulin Lispro Proteins 0.000 description 3
• COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 3
• 108010081368 Isophane Insulin Proteins 0.000 description 3
• 102000005237 Isophane Insulin Human genes 0.000 description 3
• IWVRVEIKCBFZNF-UHFFFAOYSA-N LSM-1636 Chemical compound C1CNC2CCCC3=C2N1C1=CC=C(C)C=C13 IWVRVEIKCBFZNF-UHFFFAOYSA-N 0.000 description 3
• 101710151321 Melanostatin Proteins 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
• 229920000881 Modified starch Polymers 0.000 description 3
• QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 3
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
• AAKDPDFZMNYDLR-UHFFFAOYSA-N N-methyl deoxynojirimycin Natural products CN1CC(O)C(O)C(O)C1CO AAKDPDFZMNYDLR-UHFFFAOYSA-N 0.000 description 3
• AAKDPDFZMNYDLR-XZBKPIIZSA-N N-methyl-1-deoxynojirimycin Chemical compound CN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO AAKDPDFZMNYDLR-XZBKPIIZSA-N 0.000 description 3
• RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 3
• 102400000064 Neuropeptide Y Human genes 0.000 description 3
• GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 description 3
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 3
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 3
• 229920001615 Tragacanth Polymers 0.000 description 3
• 229960002632 acarbose Drugs 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 125000000304 alkynyl group Chemical group 0.000 description 3
• 239000003888 alpha glucosidase inhibitor Substances 0.000 description 3
• 230000001195 anabolic effect Effects 0.000 description 3
• 239000002830 appetite depressant Substances 0.000 description 3
• 150000001501 aryl fluorides Chemical class 0.000 description 3
• 239000000305 astragalus gummifer gum Substances 0.000 description 3
• 125000004429 atom Chemical group 0.000 description 3
• LUCXVPAZUDVVBT-UNTBIKODSA-N atomoxetine hydrochloride Chemical compound Cl.O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C LUCXVPAZUDVVBT-UNTBIKODSA-N 0.000 description 3
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
• 150000004283 biguanides Chemical class 0.000 description 3
• 230000027455 binding Effects 0.000 description 3
• 239000012267 brine Substances 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 239000008120 corn starch Substances 0.000 description 3
• 229940099112 cornstarch Drugs 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 3
• USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000000221 dopamine uptake inhibitor Substances 0.000 description 3
• 238000012377 drug delivery Methods 0.000 description 3
• 230000009977 dual effect Effects 0.000 description 3
• 230000002124 endocrine Effects 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 235000019441 ethanol Nutrition 0.000 description 3
• NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 description 3
• 229940125753 fibrate Drugs 0.000 description 3
• 229960002464 fluoxetine Drugs 0.000 description 3
• 238000010438 heat treatment Methods 0.000 description 3
• 125000005842 heteroatom Chemical group 0.000 description 3
• 239000003395 histamine H3 receptor antagonist Substances 0.000 description 3
• 229930195733 hydrocarbon Natural products 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 229960004903 invert sugar Drugs 0.000 description 3
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
• YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 3
• MJJDYOLPMGIWND-UHFFFAOYSA-N litoxetine Chemical compound C=1C=C2C=CC=CC2=CC=1COC1CCNCC1 MJJDYOLPMGIWND-UHFFFAOYSA-N 0.000 description 3
• 239000011777 magnesium Substances 0.000 description 3
• 239000000336 melanocortin receptor agonist Substances 0.000 description 3
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
• 239000008108 microcrystalline cellulose Substances 0.000 description 3
• 229940016286 microcrystalline cellulose Drugs 0.000 description 3
• 125000002950 monocyclic group Chemical group 0.000 description 3
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 3
• 230000024121 nodulation Effects 0.000 description 3
• URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 3
• 210000000963 osteoblast Anatomy 0.000 description 3
• QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
• 239000008177 pharmaceutical agent Substances 0.000 description 3
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• 235000015320 potassium carbonate Nutrition 0.000 description 3
• TZIRZGBAFTZREM-MKAGXXMWSA-N pramlintide Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 TZIRZGBAFTZREM-MKAGXXMWSA-N 0.000 description 3
• 201000009104 prediabetes syndrome Diseases 0.000 description 3
• 229960003770 reboxetine Drugs 0.000 description 3
• 230000008929 regeneration Effects 0.000 description 3
• 238000011069 regeneration method Methods 0.000 description 3
• 229960002073 sertraline Drugs 0.000 description 3
• 239000000377 silicon dioxide Substances 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
• UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 3
• 229960004688 venlafaxine Drugs 0.000 description 3
• 229960001729 voglibose Drugs 0.000 description 3
• WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 3
• DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
• DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
• KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
• WQSACWZKKZPCHN-AWEZNQCLSA-N (1s)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1([C@@H](N)CC(C)C)CCC1 WQSACWZKKZPCHN-AWEZNQCLSA-N 0.000 description 2
• UNAANXDKBXWMLN-INIZCTEOSA-N (1s)-1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1([C@@H](N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-INIZCTEOSA-N 0.000 description 2
• GKKPXBHNFVDHAQ-USNYZCROSA-N (2r)-n-[(2r)-3-[4-[n'-[[4-[(dimethylamino)methyl]cyclohexyl]methyl]carbamimidoyl]phenyl]-1-oxo-1-pyrrolidin-1-ylpropan-2-yl]-2-(naphthalen-2-ylsulfonylamino)-3-phenylpropanamide Chemical compound C1CC(CN(C)C)CCC1CN=C(N)C(C=C1)=CC=C1C[C@H](C(=O)N1CCCC1)NC(=O)[C@H](NS(=O)(=O)C=1C=C2C=CC=CC2=CC=1)CC1=CC=CC=C1 GKKPXBHNFVDHAQ-USNYZCROSA-N 0.000 description 2
• HWEMEKZYQCJVEZ-PPHPATTJSA-N (2s)-2-[(7-fluoro-2,3-dihydro-1h-inden-4-yl)oxymethyl]morpholine;hydrochloride Chemical compound Cl.C1=2CCCC=2C(F)=CC=C1OC[C@@H]1CNCCO1 HWEMEKZYQCJVEZ-PPHPATTJSA-N 0.000 description 2
• RDGUFKZGMLPVHL-QFIPXVFZSA-N (2s)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]-2-(propylamino)propanoic acid Chemical compound C1=CC(C[C@H](NCCC)C(O)=O)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 RDGUFKZGMLPVHL-QFIPXVFZSA-N 0.000 description 2
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
• RTHCYVBBDHJXIQ-INIZCTEOSA-N (S)-fluoxetine Chemical compound O([C@@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-INIZCTEOSA-N 0.000 description 2
• QIQWRCNAPQJQLL-COALEZEGSA-N (z)-but-2-enedioic acid;5-[(1r,2r)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1h-imidazole Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)CCC#C[C@@H]1C[C@H]1C1=CN=CN1 QIQWRCNAPQJQLL-COALEZEGSA-N 0.000 description 2
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
• ZQPXSRTZFYHSFB-UHFFFAOYSA-N 1-[4-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]phenyl]propan-1-one Chemical compound C1=CC(C(=O)CC)=CC=C1OCC(O)CN1CCN(C=2C=CC=CC=2)CC1 ZQPXSRTZFYHSFB-UHFFFAOYSA-N 0.000 description 2
• GVFDJARVUPVMGP-UHFFFAOYSA-N 1-[5-[[3-methoxy-4-[4-methoxycarbonyl-2-(trifluoromethyl)phenoxy]phenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]azetidine-3-carboxylic acid Chemical compound FC(F)(F)C1=CC(C(=O)OC)=CC=C1OC(C(=C1)OC)=CC=C1C=C1C(=O)N=C(N2CC(C2)C(O)=O)S1 GVFDJARVUPVMGP-UHFFFAOYSA-N 0.000 description 2
• VOZPEPWRXVBLSJ-UHFFFAOYSA-N 1-[5-[[4-[4-cyano-2-(trifluoromethyl)phenoxy]-3-fluorophenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]azetidine-3-carboxylic acid Chemical compound C1C(C(=O)O)CN1C(S1)=NC(=O)C1=CC(C=C1F)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F VOZPEPWRXVBLSJ-UHFFFAOYSA-N 0.000 description 2
• RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 2
• 108010024665 1229U91 Proteins 0.000 description 2
• CDAISMWEOUEBRE-LKPKBOIGSA-N 1D-chiro-inositol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-LKPKBOIGSA-N 0.000 description 2
• GPCJDSXBRMKASP-UHFFFAOYSA-N 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid Chemical compound OC(=O)C(Cl)(Cl)CCCCCCCCCCC1=CC=C(Cl)C=C1 GPCJDSXBRMKASP-UHFFFAOYSA-N 0.000 description 2
• ZSTYYFFNSBKYLC-UHFFFAOYSA-N 2-[2-[(e)-(aminohydrazinylidene)methyl]hydrazinyl]acetic acid Chemical compound NNN=CNNCC(O)=O ZSTYYFFNSBKYLC-UHFFFAOYSA-N 0.000 description 2
• SABCCZAHTZTCNO-UHFFFAOYSA-N 2-[4-(3-chloropropyl)piperazin-1-yl]quinoline Chemical compound C1CN(CCCCl)CCN1C1=CC=C(C=CC=C2)C2=N1 SABCCZAHTZTCNO-UHFFFAOYSA-N 0.000 description 2
• KCEFVYIWOQSJCH-LMOVPXPDSA-N 2-[4-[2-[[(2r)-2-hydroxy-2-phenylethyl]amino]ethoxy]phenyl]acetic acid;hydrochloride Chemical compound Cl.C([C@H](O)C=1C=CC=CC=1)NCCOC1=CC=C(CC(O)=O)C=C1 KCEFVYIWOQSJCH-LMOVPXPDSA-N 0.000 description 2
• ASWYZRRXMGAWGN-UHFFFAOYSA-N 2-[[2-methoxy-2-[3-(trifluoromethyl)phenyl]ethyl]amino]ethyl 4-[2-[[2-(9h-fluoren-9-yl)acetyl]amino]ethyl]benzoate Chemical compound C=1C=C(CCNC(=O)CC2C3=CC=CC=C3C3=CC=CC=C32)C=CC=1C(=O)OCCNCC(OC)C1=CC=CC(C(F)(F)F)=C1 ASWYZRRXMGAWGN-UHFFFAOYSA-N 0.000 description 2
• RPXXWMZDSSWNFS-UHFFFAOYSA-N 2-[[5-[[4-[4-cyano-2-(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]amino]acetic acid Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(NCC(O)=O)=NC1=O RPXXWMZDSSWNFS-UHFFFAOYSA-N 0.000 description 2
• BJBCSGQLZQGGIQ-QGZVFWFLSA-N 2-acetamidoethyl (2r)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate Chemical compound O([C@@H](C(=O)OCCNC(=O)C)C=1C=CC(Cl)=CC=1)C1=CC=CC(C(F)(F)F)=C1 BJBCSGQLZQGGIQ-QGZVFWFLSA-N 0.000 description 2
• IHBAVXVTGLANPI-QMMMGPOBSA-N 2-amino-3-methyl-1-pyrrolidin-1-yl-butan-1-one Chemical compound CC(C)[C@H](N)C(=O)N1CCCC1 IHBAVXVTGLANPI-QMMMGPOBSA-N 0.000 description 2
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
• SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
• CRBJBYGJVIBWIY-UHFFFAOYSA-N 2-isopropylphenol Chemical compound CC(C)C1=CC=CC=C1O CRBJBYGJVIBWIY-UHFFFAOYSA-N 0.000 description 2
• WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
• RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 2
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
• RZDOYNNKGDDGBX-UHFFFAOYSA-N 3-chloro-4-(4-formyl-2-methoxyphenoxy)benzonitrile Chemical compound COC1=CC(C=O)=CC=C1OC1=CC=C(C#N)C=C1Cl RZDOYNNKGDDGBX-UHFFFAOYSA-N 0.000 description 2
• VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical compound NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 description 2
• JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 2
• MNCVWFCMSYUHDR-UHFFFAOYSA-N 4-(2-fluoro-4-formylphenoxy)naphthalene-1-carbonitrile Chemical compound FC1=CC(C=O)=CC=C1OC1=CC=C(C#N)C2=CC=CC=C12 MNCVWFCMSYUHDR-UHFFFAOYSA-N 0.000 description 2
• SAURKKOJWIFYSR-UHFFFAOYSA-N 4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine;hydrate;hydrochloride Chemical compound O.Cl.N1=C2SC(C)=CC2=C(C=2C(=CC=CC=2)F)N=C1N1CCNCC1 SAURKKOJWIFYSR-UHFFFAOYSA-N 0.000 description 2
• WSVZQFSIAWTUGR-UHFFFAOYSA-N 4-[2-fluoro-4-[(2-methylsulfanyl-4-oxo-1,3-thiazol-5-ylidene)methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound S1C(SC)=NC(=O)C1=CC(C=C1F)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F WSVZQFSIAWTUGR-UHFFFAOYSA-N 0.000 description 2
• IERHINHAHFYZOZ-UHFFFAOYSA-N 4-[2-fluoro-4-[(2-morpholin-4-yl-4-oxo-1,3-thiazol-5-ylidene)methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(F)=CC=1C=C(C(N=1)=O)SC=1N1CCOCC1 IERHINHAHFYZOZ-UHFFFAOYSA-N 0.000 description 2
• SLDPLSAOCDZFCB-UHFFFAOYSA-N 4-[2-fluoro-4-[[2-(2-fluoroethylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound S1C(NCCF)=NC(=O)C1=CC(C=C1F)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F SLDPLSAOCDZFCB-UHFFFAOYSA-N 0.000 description 2
• WDHVKQGABKWCJZ-UHFFFAOYSA-N 4-[2-fluoro-4-[[2-(3-hydroxypiperidin-1-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C1C(O)CCCN1C(S1)=NC(=O)C1=CC(C=C1F)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F WDHVKQGABKWCJZ-UHFFFAOYSA-N 0.000 description 2
• IYEVNMJHAJGETF-UHFFFAOYSA-N 4-[2-fluoro-4-[[2-(3-morpholin-4-ylpropylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(F)=CC=1C=C(C(N=1)=O)SC=1NCCCN1CCOCC1 IYEVNMJHAJGETF-UHFFFAOYSA-N 0.000 description 2
• RQSLUXHXORWUBL-UHFFFAOYSA-N 4-[2-fluoro-4-[[2-[2-(4-methylpiperazin-1-yl)ethylamino]-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C1CN(C)CCN1CCNC(S1)=NC(=O)C1=CC(C=C1F)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F RQSLUXHXORWUBL-UHFFFAOYSA-N 0.000 description 2
• VPOCAIZHLLXOFL-UHFFFAOYSA-N 4-[2-fluoro-4-[[2-[2-(oxan-4-yl)ethylamino]-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(F)=CC=1C=C(C(N=1)=O)SC=1NCCC1CCOCC1 VPOCAIZHLLXOFL-UHFFFAOYSA-N 0.000 description 2
• UOOBQJGSXBBHPF-UHFFFAOYSA-N 4-[2-fluoro-4-[[4-oxo-2-(2h-tetrazol-5-ylmethylamino)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(F)=CC=1C=C(C(N=1)=O)SC=1NCC1=NN=NN1 UOOBQJGSXBBHPF-UHFFFAOYSA-N 0.000 description 2
• DJUUVACFPGYCCL-UHFFFAOYSA-N 4-[2-fluoro-4-[[4-oxo-2-[3-(2-oxopyrrolidin-1-yl)propylamino]-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(F)=CC=1C=C(C(N=1)=O)SC=1NCCCN1CCCC1=O DJUUVACFPGYCCL-UHFFFAOYSA-N 0.000 description 2
• RTDGRMGTVUZFHI-UHFFFAOYSA-N 4-[2-fluoro-4-[[4-oxo-2-[3-(3-oxopiperazin-1-yl)propylamino]-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(F)=CC=1C=C(C(N=1)=O)SC=1NCCCN1CCNC(=O)C1 RTDGRMGTVUZFHI-UHFFFAOYSA-N 0.000 description 2
• ZIPKBVPEKSXRQH-UHFFFAOYSA-N 4-[2-methoxy-4-[(2-morpholin-4-yl-4-oxo-1,3-thiazol-5-ylidene)methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCOCC1 ZIPKBVPEKSXRQH-UHFFFAOYSA-N 0.000 description 2
• WNPYXBRMLPKOJL-UHFFFAOYSA-N 4-[2-methoxy-4-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(=S)NC1=O WNPYXBRMLPKOJL-UHFFFAOYSA-N 0.000 description 2
• UFBAHVGFTZZUNH-UHFFFAOYSA-N 4-[2-methoxy-4-[[2-(2-methoxyethylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound S1C(NCCOC)=NC(=O)C1=CC(C=C1OC)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F UFBAHVGFTZZUNH-UHFFFAOYSA-N 0.000 description 2
• KMCGQWLVQNXFIM-UHFFFAOYSA-N 4-[2-methoxy-4-[[2-(4-methyl-3-oxopiperazin-1-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCN(C)C(=O)C1 KMCGQWLVQNXFIM-UHFFFAOYSA-N 0.000 description 2
• WQASYMJRJPIWHR-UHFFFAOYSA-N 4-[2-methoxy-4-[[2-(methylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound S1C(NC)=NC(=O)C1=CC(C=C1OC)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F WQASYMJRJPIWHR-UHFFFAOYSA-N 0.000 description 2
• GXXRWLSIZNFCKZ-UHFFFAOYSA-N 4-[2-methoxy-4-[[2-(morpholin-2-ylmethylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCC1CNCCO1 GXXRWLSIZNFCKZ-UHFFFAOYSA-N 0.000 description 2
• KPQIIABACXQDNU-UHFFFAOYSA-N 4-[2-methoxy-4-[[2-(oxan-4-ylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NC1CCOCC1 KPQIIABACXQDNU-UHFFFAOYSA-N 0.000 description 2
• QNVGTPRTJWCOAU-UHFFFAOYSA-N 4-[2-methoxy-4-[[2-[(1-methylpiperidin-4-yl)amino]-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NC1CCN(C)CC1 QNVGTPRTJWCOAU-UHFFFAOYSA-N 0.000 description 2
• GVCGVCMPEMLFRR-UHFFFAOYSA-N 4-[2-methoxy-4-[[2-[(3-morpholin-4-yl-3-oxopropyl)amino]-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCCC(=O)N1CCOCC1 GVCGVCMPEMLFRR-UHFFFAOYSA-N 0.000 description 2
• RQSLFWRBKFBHMQ-UHFFFAOYSA-N 4-[2-methoxy-4-[[2-[2-(oxan-4-yl)ethylamino]-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCCC1CCOCC1 RQSLFWRBKFBHMQ-UHFFFAOYSA-N 0.000 description 2
• WDQGXPCDHAXQOQ-UHFFFAOYSA-N 4-[2-methoxy-4-[[2-[methoxy(methyl)amino]-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound S1C(N(C)OC)=NC(=O)C1=CC(C=C1OC)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F WDQGXPCDHAXQOQ-UHFFFAOYSA-N 0.000 description 2
• IDUPUCAUNZZYSG-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-(2-piperidin-1-ylethylamino)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCCN1CCCCC1 IDUPUCAUNZZYSG-UHFFFAOYSA-N 0.000 description 2
• QQDGHJHRHKWBSD-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-(2-pyrrolidin-1-ylethylamino)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCCN1CCCC1 QQDGHJHRHKWBSD-UHFFFAOYSA-N 0.000 description 2
• BYHRVCUFXSIJQU-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-(3-oxopiperazin-1-yl)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzamide Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C(N)=O)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCNC(=O)C1 BYHRVCUFXSIJQU-UHFFFAOYSA-N 0.000 description 2
• UTLPUNRQMZVERH-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-(pyridin-4-ylmethylamino)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCC1=CC=NC=C1 UTLPUNRQMZVERH-UHFFFAOYSA-N 0.000 description 2
• CLTORDNRUKKCPI-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-(pyrrolidin-3-ylamino)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NC1CCNC1 CLTORDNRUKKCPI-UHFFFAOYSA-N 0.000 description 2
• DEPRDKLCQZOPFY-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-[2-(1,2,4-triazol-1-yl)ethylamino]-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCCN1C=NC=N1 DEPRDKLCQZOPFY-UHFFFAOYSA-N 0.000 description 2
• OXYWZEJBIZKWAE-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-[3-(2-oxopyrrolidin-1-yl)propylamino]-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCCCN1CCCC1=O OXYWZEJBIZKWAE-UHFFFAOYSA-N 0.000 description 2
• GPJRFIVBNYTQPZ-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-[3-(3-oxopiperazin-1-yl)propylamino]-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCCCN1CCNC(=O)C1 GPJRFIVBNYTQPZ-UHFFFAOYSA-N 0.000 description 2
• XQNBJFUWFIHAMW-UHFFFAOYSA-N 4-[3-(1h-imidazol-5-yl)propoxy]benzonitrile Chemical compound C1=CC(C#N)=CC=C1OCCCC1=CN=CN1 XQNBJFUWFIHAMW-UHFFFAOYSA-N 0.000 description 2
• ZGJQRGKYKRUFQE-UHFFFAOYSA-N 4-[4-[(2-amino-4-oxo-1,3-thiazol-5-ylidene)methyl]-2-chlorophenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC(C#N)=CC=C1OC(C(=C1)Cl)=CC=C1C=C1C(=O)NC(=N)S1 ZGJQRGKYKRUFQE-UHFFFAOYSA-N 0.000 description 2
• ZMHOBDAHPNJZJG-UHFFFAOYSA-N 4-[4-[(2-amino-4-oxo-1,3-thiazol-5-ylidene)methyl]-2-fluorophenoxy]naphthalene-1-carbonitrile Chemical compound C=1C=C(OC=2C3=CC=CC=C3C(C#N)=CC=2)C(F)=CC=1C=C1SC(=N)NC1=O ZMHOBDAHPNJZJG-UHFFFAOYSA-N 0.000 description 2
• GHJJBEKMPCOSRH-LRHLLKFHSA-N 4-[4-[(2s,5s)-5-[2-(dibenzylamino)-2-oxoethyl]-2-heptyl-4-oxo-1,3-thiazolidin-3-yl]butyl]benzoic acid Chemical compound C([C@@H]1S[C@H](N(C1=O)CCCCC=1C=CC(=CC=1)C(O)=O)CCCCCCC)C(=O)N(CC=1C=CC=CC=1)CC1=CC=CC=C1 GHJJBEKMPCOSRH-LRHLLKFHSA-N 0.000 description 2
• HMFNMYZQMBQKHA-UHFFFAOYSA-N 4-[4-[[2-(2,2-difluoroethylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(NCC(F)F)=NC1=O HMFNMYZQMBQKHA-UHFFFAOYSA-N 0.000 description 2
• IECXUTNLIMSYSV-UHFFFAOYSA-N 4-[4-[[2-(2,6-dimethylmorpholin-4-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CC(C)OC(C)C1 IECXUTNLIMSYSV-UHFFFAOYSA-N 0.000 description 2
• QFDPUMGNAVVGMT-UHFFFAOYSA-N 4-[4-[[2-(2-fluoroethylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(NCCF)=NC1=O QFDPUMGNAVVGMT-UHFFFAOYSA-N 0.000 description 2
• DXPWMJQCNLVCHC-UHFFFAOYSA-N 4-[4-[[2-(3-hydroxypiperidin-1-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzamide Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C(N)=O)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCCC(O)C1 DXPWMJQCNLVCHC-UHFFFAOYSA-N 0.000 description 2
• UCVUGJVHSDPNRH-UHFFFAOYSA-N 4-[4-[[2-(3-hydroxypiperidin-1-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCCC(O)C1 UCVUGJVHSDPNRH-UHFFFAOYSA-N 0.000 description 2
• ORAHWURWHYBTSO-UHFFFAOYSA-N 4-[4-[[2-(3-hydroxypyrrolidin-1-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCC(O)C1 ORAHWURWHYBTSO-UHFFFAOYSA-N 0.000 description 2
• ITHZWNSSGHWJMN-UHFFFAOYSA-N 4-[4-[[2-[(3,5-difluorophenyl)methylamino]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCC1=CC(F)=CC(F)=C1 ITHZWNSSGHWJMN-UHFFFAOYSA-N 0.000 description 2
• NQRGVYJRAIBGRL-UHFFFAOYSA-N 4-[4-[[2-[(3-amino-2-hydroxypropyl)amino]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(NCC(O)CN)=NC1=O NQRGVYJRAIBGRL-UHFFFAOYSA-N 0.000 description 2
• BZEHWTKDULESGA-UHFFFAOYSA-N 4-[4-[[2-[2,3-dihydroxypropyl(methyl)amino]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(N(C)CC(O)CO)=NC1=O BZEHWTKDULESGA-UHFFFAOYSA-N 0.000 description 2
• PNTZYSGYKLGXBX-UHFFFAOYSA-N 4-[4-[[2-[2-(dimethylamino)ethyl-methylamino]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(N(C)CCN(C)C)=NC1=O PNTZYSGYKLGXBX-UHFFFAOYSA-N 0.000 description 2
• XDEIWGZOXVPISJ-UHFFFAOYSA-N 4-[4-[[2-[3-(dimethylamino)propylamino]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(NCCCN(C)C)=NC1=O XDEIWGZOXVPISJ-UHFFFAOYSA-N 0.000 description 2
• DZLJNTZSMOPUPF-UHFFFAOYSA-N 4-[4-[[2-[4-(2-hydroxyethyl)piperazin-1-yl]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCN(CCO)CC1 DZLJNTZSMOPUPF-UHFFFAOYSA-N 0.000 description 2
• KPJCIBFVVVTYMD-UHFFFAOYSA-N 4-[4-[[2-[4-(dimethylamino)piperidin-1-yl]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCC(N(C)C)CC1 KPJCIBFVVVTYMD-UHFFFAOYSA-N 0.000 description 2
• UFLDRJOQGCUWAW-UHFFFAOYSA-N 4-[4-[[2-[[1-(2-hydroxyethyl)piperidin-4-yl]amino]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NC1CCN(CCO)CC1 UFLDRJOQGCUWAW-UHFFFAOYSA-N 0.000 description 2
• WUJBQTCHPFESHV-UHFFFAOYSA-N 4-[4-[[2-[bis(2-hydroxyethyl)amino]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(N(CCO)CCO)=NC1=O WUJBQTCHPFESHV-UHFFFAOYSA-N 0.000 description 2
• QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 description 2
• CQZQCORFYSSCFY-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=C(C#N)C=C1C(F)(F)F CQZQCORFYSSCFY-UHFFFAOYSA-N 0.000 description 2
• FQCUYGFIIAZMLU-UHFFFAOYSA-N 5-[[2-(naphthalen-2-ylmethyl)-1,3-benzoxazol-5-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(OC(CC=2C=C3C=CC=CC3=CC=2)=N2)C2=C1 FQCUYGFIIAZMLU-UHFFFAOYSA-N 0.000 description 2
• RUEHTDFIDDAHPY-UHFFFAOYSA-N 5-[[3-methoxy-4-[2-(trifluoromethyl)phenoxy]phenyl]methylidene]-2-methylsulfanyl-1,3-thiazol-4-one Chemical compound C=1C=C(OC=2C(=CC=CC=2)C(F)(F)F)C(OC)=CC=1C=C1SC(SC)=NC1=O RUEHTDFIDDAHPY-UHFFFAOYSA-N 0.000 description 2
• MORUKGKRTLITLJ-UHFFFAOYSA-N 5-[[3-methoxy-4-[2-(trifluoromethyl)phenoxy]phenyl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=C(OC=2C(=CC=CC=2)C(F)(F)F)C(OC)=CC=1C=C1SC(=S)NC1=O MORUKGKRTLITLJ-UHFFFAOYSA-N 0.000 description 2
• PCAZCAZVHLGDBA-UHFFFAOYSA-N 5-[[4-(2-indol-1-ylethoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC(C=C1)=CC=C1OCCN1C2=CC=CC=C2C=C1 PCAZCAZVHLGDBA-UHFFFAOYSA-N 0.000 description 2
• MZRQLASUMBMPRS-UHFFFAOYSA-N 5-[[4-[2-(5-methyl-2-thiophen-2-yl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound CC=1OC(C=2SC=CC=2)=NC=1CCOC(C=1C=CSC=11)=CC=C1CC1SC(=O)NC1=O MZRQLASUMBMPRS-UHFFFAOYSA-N 0.000 description 2
• YUVNGBZROXQYQH-UHFFFAOYSA-N 5-nitro-6-(2-propan-2-ylphenyl)sulfonyl-8-quinolinamine Chemical compound CC(C)C1=CC=CC=C1S(=O)(=O)C1=CC(N)=C(N=CC=C2)C2=C1[N+]([O-])=O YUVNGBZROXQYQH-UHFFFAOYSA-N 0.000 description 2
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
• 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 2
• 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 229940127438 Amylin Agonists Drugs 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• FBMCYYWIBYEOST-GJFSDDNBSA-N BIBO-3304 Chemical compound OC(=O)C(F)(F)F.N([C@H](CCCNC(=N)N)C(=O)NCC=1C=CC(CNC(N)=O)=CC=1)C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 FBMCYYWIBYEOST-GJFSDDNBSA-N 0.000 description 2
• CIWXXQSJBGNZNJ-UHFFFAOYSA-N BMS-192548 Chemical compound COC1=CC2=C(C(O)=C1)C(=O)C1=C(O)C3(O)C(=O)C(C(C)=O)=C(O)CC3(O)CC1=C2 CIWXXQSJBGNZNJ-UHFFFAOYSA-N 0.000 description 2
• XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
• 206010065687 Bone loss Diseases 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 240000008886 Ceratonia siliqua Species 0.000 description 2
• 235000013912 Ceratonia siliqua Nutrition 0.000 description 2
• JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
• 229920001268 Cholestyramine Polymers 0.000 description 2
• 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
• 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
• 244000303965 Cyamopsis psoralioides Species 0.000 description 2
• HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 208000020401 Depressive disease Diseases 0.000 description 2
• 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
• SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
• 102000001267 GSK3 Human genes 0.000 description 2
• QTQMRBZOBKYXCG-MHZLTWQESA-N GW 1929 Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCN(C)C=1N=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 QTQMRBZOBKYXCG-MHZLTWQESA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
• 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
• 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
• 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
• 108010033040 Histones Proteins 0.000 description 2
• 101000976075 Homo sapiens Insulin Proteins 0.000 description 2
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
• MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 2
• 108010073961 Insulin Aspart Proteins 0.000 description 2
• 108010089308 Insulin Detemir Proteins 0.000 description 2
• ULXYQAJWJGLCNR-YUMQZZPRSA-N Leu-Asp-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O ULXYQAJWJGLCNR-YUMQZZPRSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 108010007859 Lisinopril Proteins 0.000 description 2
• 102000043136 MAP kinase family Human genes 0.000 description 2
• 108091054455 MAP kinase family Proteins 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
• 229940117029 Melanocortin receptor agonist Drugs 0.000 description 2
• CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
• XNCDYJFPRPDERF-PBCQUBLHSA-N Milnacipran hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1C[NH3+] XNCDYJFPRPDERF-PBCQUBLHSA-N 0.000 description 2
• UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 2
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
• AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 2
• 108010025020 Nerve Growth Factor Proteins 0.000 description 2
• 102000007072 Nerve Growth Factors Human genes 0.000 description 2
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
• 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 2
• 102000002512 Orexin Human genes 0.000 description 2
• 102000016978 Orphan receptors Human genes 0.000 description 2
• 108070000031 Orphan receptors Proteins 0.000 description 2
• 102000004264 Osteopontin Human genes 0.000 description 2
• 108010081689 Osteopontin Proteins 0.000 description 2
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
• 108010015181 PPAR delta Proteins 0.000 description 2
• 102000000536 PPAR gamma Human genes 0.000 description 2
• 102000019280 Pancreatic lipases Human genes 0.000 description 2
• 108050006759 Pancreatic lipases Proteins 0.000 description 2
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
• 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 108091027981 Response element Proteins 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 235000015125 Sterculia urens Nutrition 0.000 description 2
• 240000001058 Sterculia urens Species 0.000 description 2
• WVYIXBYYAHYOIW-UHFFFAOYSA-N TMC-2C Natural products C1=CC=C2C(CC(N)C(=O)N3C(CC4=CC(O)=C(C(=C4C3)O)OC)C(=O)NC(CC(C)CO)C(O)=O)=CNC2=C1 WVYIXBYYAHYOIW-UHFFFAOYSA-N 0.000 description 2
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 240000008042 Zea mays Species 0.000 description 2
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
• BQNGEEDNZRILLS-HZLVCURZSA-N [(1r,5r,6r,7s)-6-methyl-1,3,7-tris(3-methylbut-2-enyl)-6-(4-methylpent-3-enyl)-5-(2-methylpropanoyl)-4,9-dioxo-2-bicyclo[3.3.1]non-2-enyl] 3,4,5-trimethoxybenzoate Chemical compound COC1=C(OC)C(OC)=CC(C(=O)OC=2[C@]3(CC=C(C)C)C(=O)[C@]([C@]([C@@H](CC=C(C)C)C3)(C)CCC=C(C)C)(C(=O)C(C)C)C(=O)C=2CC=C(C)C)=C1 BQNGEEDNZRILLS-HZLVCURZSA-N 0.000 description 2
• YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 2
• 239000000853 adhesive Substances 0.000 description 2
• 230000001070 adhesive effect Effects 0.000 description 2
• 210000001789 adipocyte Anatomy 0.000 description 2
• 239000000674 adrenergic antagonist Substances 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 229940072056 alginate Drugs 0.000 description 2
• 150000001336 alkenes Chemical class 0.000 description 2
• 108010004469 allophycocyanin Proteins 0.000 description 2
• 108010028144 alpha-Glucosidases Proteins 0.000 description 2
• SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
• 230000000181 anti-adherent effect Effects 0.000 description 2
• 230000000692 anti-sense effect Effects 0.000 description 2
• 239000003911 antiadherent Substances 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 description 2
• GFZWHAAOIVMHOI-UHFFFAOYSA-N azetidine-3-carboxylic acid Chemical compound OC(=O)C1CNC1 GFZWHAAOIVMHOI-UHFFFAOYSA-N 0.000 description 2
• 235000012216 bentonite Nutrition 0.000 description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
• 239000002876 beta blocker Substances 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 230000008468 bone growth Effects 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 229910000024 caesium carbonate Inorganic materials 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229960005069 calcium Drugs 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 2
• 238000004296 chiral HPLC Methods 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000013375 chromatographic separation Methods 0.000 description 2
• 150000001860 citric acid derivatives Chemical class 0.000 description 2
• UCAIEVHKDLMIFL-UHFFFAOYSA-N clobenpropit Chemical compound C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 UCAIEVHKDLMIFL-UHFFFAOYSA-N 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 229920001577 copolymer Polymers 0.000 description 2
• 235000005822 corn Nutrition 0.000 description 2
• ACQBHJXEAYTHCY-UHFFFAOYSA-N cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone Chemical compound C=1C=C(OCCCC=2NC=NC=2)C=CC=1C(=O)C1CC1 ACQBHJXEAYTHCY-UHFFFAOYSA-N 0.000 description 2
• 229960005217 dapoxetine Drugs 0.000 description 2
• FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 2
• 229960004597 dexfenfluramine Drugs 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 2
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
• 229960002866 duloxetine Drugs 0.000 description 2
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 239000012055 enteric layer Substances 0.000 description 2
• 108010038795 estrogen receptors Proteins 0.000 description 2
• 229960001519 exenatide Drugs 0.000 description 2
• 238000013265 extended release Methods 0.000 description 2
• ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 description 2
• 229960001582 fenfluramine Drugs 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 238000003818 flash chromatography Methods 0.000 description 2
• 239000008394 flocculating agent Substances 0.000 description 2
• 238000001640 fractional crystallisation Methods 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
• 108010051307 glycyl-glycyl-proline Proteins 0.000 description 2
• 229940084937 glyset Drugs 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
• GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
• 230000013632 homeostatic process Effects 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• KEBHLNDPKPIPLI-UHFFFAOYSA-N hydron;2-(3h-inden-4-yloxymethyl)morpholine;chloride Chemical compound Cl.C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 KEBHLNDPKPIPLI-UHFFFAOYSA-N 0.000 description 2
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
• MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical group C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 229960004333 indeloxazine Drugs 0.000 description 2
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
• 239000004026 insulin derivative Substances 0.000 description 2
• 239000000543 intermediate Substances 0.000 description 2
• 229940006445 isophane insulin Drugs 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 229940093268 isordil Drugs 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 108010034529 leucyl-lysine Proteins 0.000 description 2
• UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 2
• 235000019136 lipoic acid Nutrition 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 2
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
• 229950004138 litoxetine Drugs 0.000 description 2
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 229940045623 meridia Drugs 0.000 description 2
• GOQNNKWFFWVVMV-UHFFFAOYSA-N methyl 1-[5-[[3-methoxy-4-[4-methoxycarbonyl-2-(trifluoromethyl)phenoxy]phenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C(S1)=NC(=O)C1=CC(C=C1OC)=CC=C1OC1=CC=C(C(=O)OC)C=C1C(F)(F)F GOQNNKWFFWVVMV-UHFFFAOYSA-N 0.000 description 2
• RDDCDJVSBQECQY-UHFFFAOYSA-N methyl 2-[1-[5-[[4-[4-cyano-2-(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]piperidin-4-yl]acetate Chemical compound C1CC(CC(=O)OC)CCN1C(S1)=NC(=O)C1=CC(C=C1OC)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F RDDCDJVSBQECQY-UHFFFAOYSA-N 0.000 description 2
• BCHWWADMLIKLRZ-UHFFFAOYSA-N methyl 4-[2-methoxy-4-[[4-oxo-2-(3-oxopiperazin-1-yl)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzoate Chemical compound FC(F)(F)C1=CC(C(=O)OC)=CC=C1OC(C(=C1)OC)=CC=C1C=C1C(=O)N=C(N2CC(=O)NCC2)S1 BCHWWADMLIKLRZ-UHFFFAOYSA-N 0.000 description 2
• ZVNFXGUTJZDIAS-UHFFFAOYSA-N methyl 4-[[5-[[4-[4-cyano-2-(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]amino]butanoate Chemical compound S1C(NCCCC(=O)OC)=NC(=O)C1=CC(C=C1OC)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F ZVNFXGUTJZDIAS-UHFFFAOYSA-N 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 229960001110 miglitol Drugs 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 230000009456 molecular mechanism Effects 0.000 description 2
• UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
• DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 2
• ZLNZWPYTXVFAQM-UHFFFAOYSA-N n-[2-[[5-[[4-[4-cyano-2-(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]amino]ethyl]acetamide Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(NCCNC(C)=O)=NC1=O ZLNZWPYTXVFAQM-UHFFFAOYSA-N 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
• 229960003086 naltrexone Drugs 0.000 description 2
• 239000003900 neurotrophic factor Substances 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 2
• 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 2
• 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
• 108060005714 orexin Proteins 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 229940116369 pancreatic lipase Drugs 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 229960005183 paroxetine hydrochloride Drugs 0.000 description 2
• GELRVIPPMNMYGS-RVXRQPKJSA-N paroxetine hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 GELRVIPPMNMYGS-RVXRQPKJSA-N 0.000 description 2
• 229920001277 pectin Polymers 0.000 description 2
• 235000010987 pectin Nutrition 0.000 description 2
• 239000001814 pectin Substances 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 229960003562 phentermine Drugs 0.000 description 2
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
• 229960005095 pioglitazone Drugs 0.000 description 2
• RMCNETIHECSPMZ-UHFFFAOYSA-N piperidine-3,4,5-triol Chemical compound OC1CNCC(O)C1O RMCNETIHECSPMZ-UHFFFAOYSA-N 0.000 description 2
• 229950002220 pirlindole Drugs 0.000 description 2
• 229960002797 pitavastatin Drugs 0.000 description 2
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 229960003611 pramlintide Drugs 0.000 description 2
• NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 2
• 229960004457 pramlintide acetate Drugs 0.000 description 2
• 238000004237 preparative chromatography Methods 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 229940035613 prozac Drugs 0.000 description 2
• XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
• CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000033458 reproduction Effects 0.000 description 2
• CRPGRUONUFDYBG-UHFFFAOYSA-N risarestat Chemical compound C1=C(OCC)C(OCCCCC)=CC=C1C1C(=O)NC(=O)S1 CRPGRUONUFDYBG-UHFFFAOYSA-N 0.000 description 2
• 230000001235 sensitizing effect Effects 0.000 description 2
• 239000003727 serotonin 1A antagonist Substances 0.000 description 2
• 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 2
• MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 2
• WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 229910000104 sodium hydride Inorganic materials 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 229940032147 starch Drugs 0.000 description 2
• 230000000707 stereoselective effect Effects 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 229940099093 symlin Drugs 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• 229920001059 synthetic polymer Polymers 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 229940099419 targretin Drugs 0.000 description 2
• CGIIDXKRBSHVCO-UHFFFAOYSA-N tert-butyl 2-[[[5-[[4-[4-cyano-2-(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]amino]methyl]morpholine-4-carboxylate Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCC1CN(C(=O)OC(C)(C)C)CCO1 CGIIDXKRBSHVCO-UHFFFAOYSA-N 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 150000001467 thiazolidinediones Chemical class 0.000 description 2
• 229960005138 tianeptine Drugs 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 229940055755 tricor Drugs 0.000 description 2
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
• 229960001641 troglitazone Drugs 0.000 description 2
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
• 239000002691 unilamellar liposome Substances 0.000 description 2
• UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 description 2
• MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
• FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 2
• 235000012141 vanillin Nutrition 0.000 description 2
• SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 description 2
• 239000001993 wax Substances 0.000 description 2
• HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
• VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
• GBLRQXKSCRCLBZ-YVQAASCFSA-N (1R,2S,1'R,2'S)-doxacurium Chemical compound COC1=C(OC)C(OC)=CC(C[C@H]2[N@+](CCC3=C2C(=C(OC)C(OC)=C3)OC)(C)CCCOC(=O)CCC(=O)OCCC[N@@+]2(C)[C@@H](C3=C(OC)C(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=C(OC)C=2)=C1 GBLRQXKSCRCLBZ-YVQAASCFSA-N 0.000 description 1
• XUSCOHKHRDQKCI-ARFHVFGLSA-N (1S,9R,10R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2,4,6-trien-13-one Chemical compound C1C(=O)CC[C@H]2[C@]3([H])NCC[C@@]21C1=CC=CC=C1C3 XUSCOHKHRDQKCI-ARFHVFGLSA-N 0.000 description 1
• UNAANXDKBXWMLN-MRXNPFEDSA-N (1r)-1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1([C@H](N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-MRXNPFEDSA-N 0.000 description 1
• XNCDYJFPRPDERF-NQQJLSKUSA-N (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropane-1-carboxamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1[C@]1(C(=O)N(CC)CC)C[C@H]1CN XNCDYJFPRPDERF-NQQJLSKUSA-N 0.000 description 1
• NEQSWPCDHDQINX-MRXNPFEDSA-N (2R)-3-cyclopentyl-2-(4-methylsulfonylphenyl)-N-(2-thiazolyl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](C(=O)NC=1SC=CN=1)CC1CCCC1 NEQSWPCDHDQINX-MRXNPFEDSA-N 0.000 description 1
• BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 description 1
• FOPYPXYFIMTSMM-PKPIPKONSA-N (2r)-2-(dithiolan-3-yl)pentanoic acid Chemical compound CCC[C@H](C(O)=O)C1CCSS1 FOPYPXYFIMTSMM-PKPIPKONSA-N 0.000 description 1
• LENOCDXQTFXGDU-XMMPIXPASA-N (2r)-2-[(2,2-diphenylacetyl)amino]-5-(hydrazinylmethylideneamino)-n-[(4-hydroxyphenyl)methyl]pentanamide Chemical compound N([C@H](CCCN=CNN)C(=O)NCC=1C=CC(O)=CC=1)C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 LENOCDXQTFXGDU-XMMPIXPASA-N 0.000 description 1
• WMUIIGVAWPWQAW-XMMPIXPASA-N (2r)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid Chemical compound C1=CC(C[C@@H](OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OC2=CC=CC=C21 WMUIIGVAWPWQAW-XMMPIXPASA-N 0.000 description 1
• BFNXYSZBURSNHS-UVJOBNTFSA-N (2s)-1-[(2s)-6-amino-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 BFNXYSZBURSNHS-UVJOBNTFSA-N 0.000 description 1
• CBQGYUDMJHNJBX-RBUKOAKNSA-N (2s)-2-[(r)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-RBUKOAKNSA-N 0.000 description 1
• QNDFBOXBUCDYNZ-NRFANRHFSA-N (2s)-2-ethoxy-3-[4-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethoxy]phenyl]propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(NC(=O)OC(C)(C)C)C=C1 QNDFBOXBUCDYNZ-NRFANRHFSA-N 0.000 description 1
• HFBHOAHFRNLZGN-LURJTMIESA-N (2s)-2-formamido-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC=O HFBHOAHFRNLZGN-LURJTMIESA-N 0.000 description 1
• WCRLBFHWFPELKW-YUMQZZPRSA-N (2s,3s)-2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCSC1 WCRLBFHWFPELKW-YUMQZZPRSA-N 0.000 description 1
• OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 description 1
• BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
• NDVZIUGCCMZHLG-OAHLLOKOSA-N (3r)-n-methyl-3-(2-methylsulfanylphenoxy)-3-phenylpropan-1-amine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1SC NDVZIUGCCMZHLG-OAHLLOKOSA-N 0.000 description 1
• VYTCDVWNUIRJEU-MFVUMRCOSA-N (3s)-3-[[(2s)-2-acetamidohexanoyl]amino]-4-[[(2s)-1-[[(2r)-1-[[(2s)-5-(diaminomethylideneamino)-1-[[(2s)-1-[[(2s)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-i Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(C)=O)CCCC)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 VYTCDVWNUIRJEU-MFVUMRCOSA-N 0.000 description 1
• MQZOATSIFWSKKT-OASXIEIISA-N (3s,4r)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine;hydrate;dihydrochloride Chemical compound O.Cl.Cl.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 MQZOATSIFWSKKT-OASXIEIISA-N 0.000 description 1
• GGYWLZFXFKFWKL-GLWNXGLNSA-N (3s,6s,9r,12s,15r,23s)-15-[[(2r)-2-acetamidohexanoyl]amino]-6-[3-(diaminomethylideneamino)propyl]-12-(1h-imidazol-5-ylmethyl)-3-(1h-indol-3-ylmethyl)-9-(naphthalen-2-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide Chemical compound C([C@H]1C(=O)N[C@H](CC=2C=C3C=CC=CC3=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCNC(=O)C[C@H](C(N1)=O)NC(=O)[C@H](NC(C)=O)CCCC)C(N)=O)C1=CNC=N1 GGYWLZFXFKFWKL-GLWNXGLNSA-N 0.000 description 1
• JDKLPDJLXHXHNV-MFVUMRCOSA-N (3s,6s,9r,12s,15s,23s)-15-[[(2s)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1h-imidazol-5-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide Chemical compound C([C@@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCNC(=O)C[C@@H](C(N[C@@H](CC=2NC=NC=2)C(=O)N1)=O)NC(=O)[C@@H](NC(C)=O)CCCC)C(N)=O)C1=CC=CC=C1 JDKLPDJLXHXHNV-MFVUMRCOSA-N 0.000 description 1
• GXPHKUHSUJUWKP-CYFREDJKSA-N (5s)-5-[[4-[[(2s)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl]methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound C([C@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-CYFREDJKSA-N 0.000 description 1
• 108700018162 (Nle(4),Phe(p-I)7)- alpha-MSH (1-13)amide Proteins 0.000 description 1
• BFFSMCNJSOPUAY-LMOVPXPDSA-N (S)-duloxetine hydrochloride Chemical compound Cl.C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 BFFSMCNJSOPUAY-LMOVPXPDSA-N 0.000 description 1
• WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
• DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
• BRIPGNJWPCKDQZ-WXXKFALUSA-N (e)-but-2-enedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 BRIPGNJWPCKDQZ-WXXKFALUSA-N 0.000 description 1
• GHADIQOLHLUYIM-GZTJUZNOSA-N (ne)-n-[1-[4-[3-(1h-imidazol-5-yl)propoxy]phenyl]ethylidene]hydroxylamine Chemical compound C1=CC(C(=N/O)/C)=CC=C1OCCCC1=CNC=N1 GHADIQOLHLUYIM-GZTJUZNOSA-N 0.000 description 1
• VPTANTFMKCQZHV-TZKOHIRVSA-N (z)-but-2-enedioic acid;5-[(z)-6-cyclohexylhex-3-enyl]-1h-imidazole Chemical compound OC(=O)\C=C/C(O)=O.C=1N=CNC=1CC\C=C/CCC1CCCCC1 VPTANTFMKCQZHV-TZKOHIRVSA-N 0.000 description 1
• PAHVTLRWCQYFEB-UHFFFAOYSA-N 1,2-oxazolidine-3,5-dione Chemical compound O=C1CC(=O)ON1 PAHVTLRWCQYFEB-UHFFFAOYSA-N 0.000 description 1
• FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
• YCHJPZFUSHPXRT-UHFFFAOYSA-N 1,4-diazatetracyclo[7.6.1.05,16.010,15]hexadeca-3,5,7,9(16),10,12,14-heptaene Chemical compound C12=CC=CC=C2N2CC=NC3=CC=CC1=C32 YCHJPZFUSHPXRT-UHFFFAOYSA-N 0.000 description 1
• FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
• RLCVJYKAOMJMNT-UHFFFAOYSA-N 1-(hydroxymethyl)piperidine-3,4,5-triol Chemical compound OCN1CC(O)C(O)C(O)C1 RLCVJYKAOMJMNT-UHFFFAOYSA-N 0.000 description 1
• FDOYGLCMRDGPPR-UHFFFAOYSA-N 1-[1-(3,4-dichlorophenyl)cyclobutyl]-2-[3-(dimethylamino)propylsulfanyl]ethanone Chemical compound C=1C=C(Cl)C(Cl)=CC=1C1(C(=O)CSCCCN(C)C)CCC1 FDOYGLCMRDGPPR-UHFFFAOYSA-N 0.000 description 1
• WSDSEIUBXJOEIQ-UHFFFAOYSA-N 1-[1-(3-ethoxyphenyl)-4-methylcyclohexyl]-4-phenylpiperazine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCOC1=CC=CC(C2(CCC(C)CC2)N2CCN(CC2)C=2C=CC=CC=2)=C1 WSDSEIUBXJOEIQ-UHFFFAOYSA-N 0.000 description 1
• KHRVYINTXCWNRF-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine;hydron;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N)CC(C)C)CCC1 KHRVYINTXCWNRF-UHFFFAOYSA-N 0.000 description 1
• PLXKZKLXYHLWHR-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,3-dimethylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1(C(CC(C)C)NC)CCC1 PLXKZKLXYHLWHR-UHFFFAOYSA-N 0.000 description 1
• XHHLNSWTGQCLAS-MHZLTWQESA-N 1-[2-[(4-chlorophenoxy)methyl]-1-[3-[(3s)-piperidin-3-yl]propyl]indol-3-yl]-2-(4-piperidin-1-ylpiperidin-1-yl)ethanone Chemical compound C1=CC(Cl)=CC=C1OCC(N(C1=CC=CC=C11)CCC[C@H]2CNCCC2)=C1C(=O)CN1CCC(N2CCCCC2)CC1 XHHLNSWTGQCLAS-MHZLTWQESA-N 0.000 description 1
• KZZIVOLMJPSDEP-UHFFFAOYSA-N 1-[3-(4-fluorophenyl)-3-pyridin-2-ylpropyl]-2-[3-(1h-imidazol-5-yl)propyl]guanidine Chemical class C=1N=CNC=1CCCN=C(N)NCCC(C=1N=CC=CC=1)C1=CC=C(F)C=C1 KZZIVOLMJPSDEP-UHFFFAOYSA-N 0.000 description 1
• TZZGTNZBLPCBIS-UHFFFAOYSA-N 1-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-methoxy-3,4-dihydroquinolin-2-one Chemical compound O=C1CCC=2C(OC)=CC=CC=2N1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 TZZGTNZBLPCBIS-UHFFFAOYSA-N 0.000 description 1
• ITOJPDNONZGUKB-UHFFFAOYSA-N 1-[5-(4-nitrophenoxy)pentyl]pyrrolidine Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCCCCCN1CCCC1 ITOJPDNONZGUKB-UHFFFAOYSA-N 0.000 description 1
• FZKBWHATZXQBRD-UHFFFAOYSA-N 1-[5-[[4-[4-cyano-2-(trifluoromethyl)phenoxy]-3-ethoxyphenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]azetidine-3-carboxylic acid Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OCC)=CC=1C=C(C(N=1)=O)SC=1N1CC(C(O)=O)C1 FZKBWHATZXQBRD-UHFFFAOYSA-N 0.000 description 1
• NRKSJHIPWOQYPY-UHFFFAOYSA-N 1-[5-[[4-[4-cyano-2-(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]azetidine-3-carboxylic acid Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CC(C(O)=O)C1 NRKSJHIPWOQYPY-UHFFFAOYSA-N 0.000 description 1
• YLLNASGHFCLRBZ-UHFFFAOYSA-N 1-[5-[[4-[4-cyano-2-(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]piperidine-4-carboxamide Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCC(C(N)=O)CC1 YLLNASGHFCLRBZ-UHFFFAOYSA-N 0.000 description 1
• MCBXEDUXTLFFBP-UHFFFAOYSA-N 1-[7-[(dimethylamino)methyl]-4-methoxy-7-bicyclo[4.2.0]octa-1(6),2,4-trienyl]cyclopentan-1-ol Chemical compound C12=CC(OC)=CC=C2CC1(CN(C)C)C1(O)CCCC1 MCBXEDUXTLFFBP-UHFFFAOYSA-N 0.000 description 1
• DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
• QHKJIJXBJCOABP-UHFFFAOYSA-N 1-benzofuran-2-carboxamide Chemical compound C1=CC=C2OC(C(=O)N)=CC2=C1 QHKJIJXBJCOABP-UHFFFAOYSA-N 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
• CHBOSHOWERDCMH-UHFFFAOYSA-N 1-chloro-2,2-bis(4-chlorophenyl)ethane Chemical compound C=1C=C(Cl)C=CC=1C(CCl)C1=CC=C(Cl)C=C1 CHBOSHOWERDCMH-UHFFFAOYSA-N 0.000 description 1
• PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• RJRBRCCJETZJLT-GSICZYLSSA-N 1229u91 Chemical compound C([C@H](NC(=O)C1CNC(=O)CC[C@@H](C(=O)N2CCC[C@H]2C(=O)NC(CNC(=O)CC[C@@H](C(N2CCC[C@H]2C(=O)N1)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 RJRBRCCJETZJLT-GSICZYLSSA-N 0.000 description 1
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
• ODMMNALOCMNQJZ-UHFFFAOYSA-N 1H-pyrrolizine Chemical compound C1=CC=C2CC=CN21 ODMMNALOCMNQJZ-UHFFFAOYSA-N 0.000 description 1
• OZAIFHULBGXAKX-UHFFFAOYSA-N 2,2'-azo-bis-isobutyronitrile Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
• IFFLKGMDBKQMAH-UHFFFAOYSA-N 2,4-diaminopyridine Chemical class NC1=CC=NC(N)=C1 IFFLKGMDBKQMAH-UHFFFAOYSA-N 0.000 description 1
• MKHAXQCNBLLNOW-UHFFFAOYSA-N 2,5,5-tris(4-chlorophenyl)-1,3-dioxane-2-carboxylic acid Chemical compound C1OC(C(=O)O)(C=2C=CC(Cl)=CC=2)OCC1(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 MKHAXQCNBLLNOW-UHFFFAOYSA-N 0.000 description 1
• UHKTVXJWLOAFTI-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-[2-(3,4-dimethoxyphenyl)ethyliminomethyl]-5-(trifluoromethyl)-1H-pyrazol-3-one Chemical compound COC1=C(C=C(C=C1)CCN=CC2=C(NN(C2=O)C3=NC4=CC=CC=C4S3)C(F)(F)F)OC UHKTVXJWLOAFTI-UHFFFAOYSA-N 0.000 description 1
• GKGFUHLSCRCKTM-UHFFFAOYSA-N 2-(1-benzylpiperidin-4-yl)-1-[4-[(5-methylpyrimidin-4-yl)amino]phenyl]ethanone Chemical compound CC1=CN=CN=C1NC1=CC=C(C(=O)CC2CCN(CC=3C=CC=CC=3)CC2)C=C1 GKGFUHLSCRCKTM-UHFFFAOYSA-N 0.000 description 1
• KUXGUCNZFCVULO-UHFFFAOYSA-N 2-(4-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=C(OCCO)C=C1 KUXGUCNZFCVULO-UHFFFAOYSA-N 0.000 description 1
• ZOQOPXVJANRGJZ-UHFFFAOYSA-N 2-(trifluoromethyl)phenol Chemical compound OC1=CC=CC=C1C(F)(F)F ZOQOPXVJANRGJZ-UHFFFAOYSA-N 0.000 description 1
• MOMFXATYAINJML-UHFFFAOYSA-N 2-Acetylthiazole Chemical group CC(=O)C1=NC=CS1 MOMFXATYAINJML-UHFFFAOYSA-N 0.000 description 1
• IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
• HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
• QDOHDBQVCORQPB-UHFFFAOYSA-N 2-[2-chloro-4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound ClC1=C(OC2=C(C#N)C=CC=C2C(F)(F)F)C=CC(=C1)C=C1C(NC(S1)=O)=O QDOHDBQVCORQPB-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• VGSJXSLGVQINOL-UHFFFAOYSA-N 2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenoxy]-2-methylbutanoic acid Chemical compound C=1C=C(F)C=C(F)C=1NC(=O)N(CCCCCCC)CCC1=CC=C(OC(C)(CC)C(O)=O)C=C1 VGSJXSLGVQINOL-UHFFFAOYSA-N 0.000 description 1
• NECJNLXOJRDELU-UHFFFAOYSA-N 2-[4-[4-(5-fluoro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]butyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCCCN(CC1)CC=C1C1=CNC2=CC=C(F)C=C21 NECJNLXOJRDELU-UHFFFAOYSA-N 0.000 description 1
• NKMFSXOIHSQSSD-UHFFFAOYSA-N 2-[[5-[[4-[4-cyano-2-(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]amino]ethylurea Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(NCCNC(N)=O)=NC1=O NKMFSXOIHSQSSD-UHFFFAOYSA-N 0.000 description 1
• HRLLBWIAWUMBRH-UHFFFAOYSA-N 2-[amino(carbamohydrazonoyl)amino]acetic acid Chemical compound NNC(=N)N(N)CC(O)=O HRLLBWIAWUMBRH-UHFFFAOYSA-N 0.000 description 1
• GSSUGDUOJLAOIJ-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]-5-[[4-[2,4-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-1,3-thiazol-4-one Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C(F)(F)F)C(F)(F)F)C(OC)=CC=1C=C1SC(N(CCO)CCO)=NC1=O GSSUGDUOJLAOIJ-UHFFFAOYSA-N 0.000 description 1
• CCTREOMTIFSZAU-OGFXRTJISA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;5-[(3r)-dithiolan-3-yl]pentanoic acid Chemical compound OCC(N)(CO)CO.OC(=O)CCCC[C@@H]1CCSS1 CCTREOMTIFSZAU-OGFXRTJISA-N 0.000 description 1
• BZYKPGALHVQJQV-SFHVURJKSA-N 2-cyclopenta[c]pyran-1-yl-n-[[(1r)-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]methyl]-n-methylethanamine Chemical compound O1C=CC2=CC=CC2=C1CCN(C)C[C@H]1C(C=CC=C2OC)=C2CCC1 BZYKPGALHVQJQV-SFHVURJKSA-N 0.000 description 1
• OXRCIXHTUHZNRY-UHFFFAOYSA-N 2-cyclopentylacetamide Chemical compound NC(=O)CC1CCCC1 OXRCIXHTUHZNRY-UHFFFAOYSA-N 0.000 description 1
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
• YKWQYXWAXZJRLH-UHFFFAOYSA-N 2-hydroxy-1-(1h-imidazol-2-yl)butan-1-one Chemical class CCC(O)C(=O)C1=NC=CN1 YKWQYXWAXZJRLH-UHFFFAOYSA-N 0.000 description 1
• ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
• LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
• 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
• DKFVEDKCRIZEEM-UHFFFAOYSA-N 3-(1h-imidazol-5-yl)propan-1-ol Chemical class OCCCC1=CNC=N1 DKFVEDKCRIZEEM-UHFFFAOYSA-N 0.000 description 1
• FWYRGHMKHZXXQX-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-2-(dimethylamino)-2-methylpropan-1-ol Chemical compound CN(C)C(C)(CO)CC1=CC=C(Cl)C(Cl)=C1 FWYRGHMKHZXXQX-UHFFFAOYSA-N 0.000 description 1
• FBWFMFJYAIKZIC-UHFFFAOYSA-N 3-[2-[[3-(4-fluorophenyl)phenyl]methylamino]ethoxy]benzonitrile Chemical compound C1=CC(F)=CC=C1C1=CC=CC(CNCCOC=2C=C(C=CC=2)C#N)=C1 FBWFMFJYAIKZIC-UHFFFAOYSA-N 0.000 description 1
• PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical group [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 1
• 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
• ZCTUMAPDQABUPF-UHFFFAOYSA-N 3-chloro-4-[2-methoxy-4-[[4-oxo-2-(3-oxopiperazin-1-yl)-1,3-thiazol-5-ylidene]methyl]phenoxy]benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)Cl)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCNC(=O)C1 ZCTUMAPDQABUPF-UHFFFAOYSA-N 0.000 description 1
• BCBQLJKRGNYRQN-UHFFFAOYSA-N 3-chloro-4-[2-methoxy-4-[[4-oxo-2-[2-(2-oxopyrrolidin-1-yl)ethylamino]-1,3-thiazol-5-ylidene]methyl]phenoxy]benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)Cl)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCCN1CCCC1=O BCBQLJKRGNYRQN-UHFFFAOYSA-N 0.000 description 1
• OGXLMILEPKYMNI-UHFFFAOYSA-N 3-chloro-4-[4-[[2-[2,3-dihydroxypropyl(methyl)amino]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)Cl)C(OC)=CC=1C=C1SC(N(C)CC(O)CO)=NC1=O OGXLMILEPKYMNI-UHFFFAOYSA-N 0.000 description 1
• VAHXXQJJZKBZDX-UHFFFAOYSA-N 3-chloro-4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1Cl VAHXXQJJZKBZDX-UHFFFAOYSA-N 0.000 description 1
• VGSOCYWCRMXQAB-UHFFFAOYSA-N 3-chloro-4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1Cl VGSOCYWCRMXQAB-UHFFFAOYSA-N 0.000 description 1
• QSBHJTCAPWOIIE-UHFFFAOYSA-N 3-fluoro-4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1F QSBHJTCAPWOIIE-UHFFFAOYSA-N 0.000 description 1
• PPXMBWTZRVDXQJ-UHFFFAOYSA-N 3-methoxy-4-[2-(trifluoromethyl)phenoxy]benzaldehyde Chemical compound COC1=CC(C=O)=CC=C1OC1=CC=CC=C1C(F)(F)F PPXMBWTZRVDXQJ-UHFFFAOYSA-N 0.000 description 1
• LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 1
• QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 1
• MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
• KSBIZZTZRWDLMM-UHFFFAOYSA-N 4-(2-fluoro-4-formylphenoxy)-3-(trifluoromethyl)benzonitrile Chemical compound FC1=CC(C=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F KSBIZZTZRWDLMM-UHFFFAOYSA-N 0.000 description 1
• LGSOKZOQANLOEU-UHFFFAOYSA-N 4-[2-(2,4-dioxo-1,3-thiazolidin-5-yl)ethoxy]benzonitrile Chemical compound S1C(=O)NC(=O)C1CCOC1=CC=C(C#N)C=C1 LGSOKZOQANLOEU-UHFFFAOYSA-N 0.000 description 1
• SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
• QDDNWAZYMKBFDJ-UHFFFAOYSA-N 4-[2-chloro-4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC(C#N)=CC=C1OC(C(=C1)Cl)=CC=C1C=C1C(=O)NC(=O)S1 QDDNWAZYMKBFDJ-UHFFFAOYSA-N 0.000 description 1
• KDPZRYREYQKTGD-UHFFFAOYSA-N 4-[2-ethoxy-4-[[4-oxo-2-(3-oxopiperazin-1-yl)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OCC)=CC=1C=C(C(N=1)=O)SC=1N1CCNC(=O)C1 KDPZRYREYQKTGD-UHFFFAOYSA-N 0.000 description 1
• XGFCHOVFYGPJHD-UHFFFAOYSA-N 4-[2-fluoro-4-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(F)=CC=1C=C1SC(=S)NC1=O XGFCHOVFYGPJHD-UHFFFAOYSA-N 0.000 description 1
• UOMOHGQOUHEBBT-UHFFFAOYSA-N 4-[2-fluoro-4-[[2-(3-hydroxypyrrolidin-1-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C1C(O)CCN1C(S1)=NC(=O)C1=CC(C=C1F)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F UOMOHGQOUHEBBT-UHFFFAOYSA-N 0.000 description 1
• DZEAUHZBFRWBEL-UHFFFAOYSA-N 4-[2-fluoro-4-[[2-(4-methyl-3-oxopiperazin-1-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C1C(=O)N(C)CCN1C(S1)=NC(=O)C1=CC(C=C1F)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F DZEAUHZBFRWBEL-UHFFFAOYSA-N 0.000 description 1
• VRZJOXPQJHCJSM-UHFFFAOYSA-N 4-[2-fluoro-4-[[2-(4-methylpiperazin-1-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C1CN(C)CCN1C(S1)=NC(=O)C1=CC(C=C1F)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F VRZJOXPQJHCJSM-UHFFFAOYSA-N 0.000 description 1
• VOBDGQDTQAWJNI-UHFFFAOYSA-N 4-[2-fluoro-4-[[2-[[1-(2-hydroxyethyl)piperidin-4-yl]amino]-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C1CN(CCO)CCC1NC(S1)=NC(=O)C1=CC(C=C1F)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F VOBDGQDTQAWJNI-UHFFFAOYSA-N 0.000 description 1
• OYELVRXAMPHDCQ-UHFFFAOYSA-N 4-[2-fluoro-4-[[4-oxo-2-(3-oxopiperazin-1-yl)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(F)=CC=1C=C(C(N=1)=O)SC=1N1CCNC(=O)C1 OYELVRXAMPHDCQ-UHFFFAOYSA-N 0.000 description 1
• JBJJOUOKVNXRAM-UHFFFAOYSA-N 4-[2-fluoro-4-[[4-oxo-2-[2-(3-oxopiperazin-1-yl)ethylamino]-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(F)=CC=1C=C(C(N=1)=O)SC=1NCCN1CCNC(=O)C1 JBJJOUOKVNXRAM-UHFFFAOYSA-N 0.000 description 1
• XTTONSXCELWNNB-UHFFFAOYSA-N 4-[2-methoxy-4-[[2-(4-methylpiperazin-1-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCN(C)CC1 XTTONSXCELWNNB-UHFFFAOYSA-N 0.000 description 1
• QIXPZKPTNLAUKS-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-(2-pyridin-3-ylethylamino)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCCC1=CC=CN=C1 QIXPZKPTNLAUKS-UHFFFAOYSA-N 0.000 description 1
• OJVCZOBDMSNMTL-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-(2-pyridin-4-ylethylamino)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCCC1=CC=NC=C1 OJVCZOBDMSNMTL-UHFFFAOYSA-N 0.000 description 1
• QSSQHUHNIXVJPP-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-(2h-tetrazol-5-ylmethylamino)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCC1=NN=NN1 QSSQHUHNIXVJPP-UHFFFAOYSA-N 0.000 description 1
• JBYBRFVTFRLTQA-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-(3-oxopiperazin-1-yl)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCNC(=O)C1 JBYBRFVTFRLTQA-UHFFFAOYSA-N 0.000 description 1
• CNTHUMCEOJSTQY-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-(pyridin-2-ylmethylamino)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCC1=CC=CC=N1 CNTHUMCEOJSTQY-UHFFFAOYSA-N 0.000 description 1
• FMPUORVWUDCTFI-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-(pyridin-3-ylmethylamino)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCC1=CC=CN=C1 FMPUORVWUDCTFI-UHFFFAOYSA-N 0.000 description 1
• WAJFXIVWHJBIRZ-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-(thiophen-3-ylmethylamino)-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCC=1C=CSC=1 WAJFXIVWHJBIRZ-UHFFFAOYSA-N 0.000 description 1
• JAKIXWDIRFRAAN-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-[2-(2-oxopyrrolidin-1-yl)ethylamino]-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCCN1CCCC1=O JAKIXWDIRFRAAN-UHFFFAOYSA-N 0.000 description 1
• VEVIUGORXSGGPB-UHFFFAOYSA-N 4-[2-methoxy-4-[[4-oxo-2-[2-(3-oxopiperazin-1-yl)ethylamino]-1,3-thiazol-5-ylidene]methyl]phenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCCN1CCNC(=O)C1 VEVIUGORXSGGPB-UHFFFAOYSA-N 0.000 description 1
• FNQTYDVCGYAVTD-UHFFFAOYSA-N 4-[4-[(2-amino-4-oxo-1,3-thiazol-5-ylidene)methyl]-2-methoxyphenoxy]-3-chlorobenzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)Cl)C(OC)=CC=1C=C1SC(N)=NC1=O FNQTYDVCGYAVTD-UHFFFAOYSA-N 0.000 description 1
• RLPPBIBTVONXEC-UHFFFAOYSA-N 4-[4-[[2-(2,2-difluoroethylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-fluorophenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound S1C(NCC(F)F)=NC(=O)C1=CC(C=C1F)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F RLPPBIBTVONXEC-UHFFFAOYSA-N 0.000 description 1
• WSETXGWWUKZWPK-UHFFFAOYSA-N 4-[4-[[2-(2,6-dimethylmorpholin-4-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-fluorophenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C1C(C)OC(C)CN1C(S1)=NC(=O)C1=CC(C=C1F)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F WSETXGWWUKZWPK-UHFFFAOYSA-N 0.000 description 1
• NXUUEZHGEGNRDM-UHFFFAOYSA-N 4-[4-[[2-(2-aminoethylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(NCCN)=NC1=O NXUUEZHGEGNRDM-UHFFFAOYSA-N 0.000 description 1
• YMBGRALAWPDGNB-UHFFFAOYSA-N 4-[4-[[2-(2-hydroxyethylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(NCCO)=NC1=O YMBGRALAWPDGNB-UHFFFAOYSA-N 0.000 description 1
• SSHLQHITBQZEJK-UHFFFAOYSA-N 4-[4-[[2-(4-acetylpiperazin-1-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCN(C(C)=O)CC1 SSHLQHITBQZEJK-UHFFFAOYSA-N 0.000 description 1
• LPMAZKXKGYKBQI-UHFFFAOYSA-N 4-[4-[[2-(4-ethylsulfonylpiperazin-1-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C1CN(S(=O)(=O)CC)CCN1C(S1)=NC(=O)C1=CC(C=C1OC)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F LPMAZKXKGYKBQI-UHFFFAOYSA-N 0.000 description 1
• VLMGQLLPPZAQNL-UHFFFAOYSA-N 4-[4-[[2-(cyclopropylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-fluorophenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(F)=CC=1C=C(C(N=1)=O)SC=1NC1CC1 VLMGQLLPPZAQNL-UHFFFAOYSA-N 0.000 description 1
• OAWDMDTXDAXKFD-UHFFFAOYSA-N 4-[4-[[2-(cyclopropylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NC1CC1 OAWDMDTXDAXKFD-UHFFFAOYSA-N 0.000 description 1
• SAJSBWKWBFUQCA-UHFFFAOYSA-N 4-[4-[[2-(dimethylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(N(C)C)=NC1=O SAJSBWKWBFUQCA-UHFFFAOYSA-N 0.000 description 1
• JOZYKJJWQJSNKF-UHFFFAOYSA-N 4-[4-[[2-(furan-3-ylmethylamino)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1NCC=1C=COC=1 JOZYKJJWQJSNKF-UHFFFAOYSA-N 0.000 description 1
• VJQOPAPPXUFNGR-UHFFFAOYSA-N 4-[4-[[2-[2,3-dihydroxypropyl(methyl)amino]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-fluorophenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound S1C(N(CC(O)CO)C)=NC(=O)C1=CC(C=C1F)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F VJQOPAPPXUFNGR-UHFFFAOYSA-N 0.000 description 1
• FGJPOPYQVXUSTN-UHFFFAOYSA-N 4-[4-[[2-[2-(2-hydroxyethoxy)ethylamino]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(NCCOCCO)=NC1=O FGJPOPYQVXUSTN-UHFFFAOYSA-N 0.000 description 1
• JISHLNCGYQAHIW-UHFFFAOYSA-N 4-[4-[[2-[2-aminoethyl(methyl)amino]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(N(C)CCN)=NC1=O JISHLNCGYQAHIW-UHFFFAOYSA-N 0.000 description 1
• FNORKXYVHGIFEP-UHFFFAOYSA-N 4-[4-[[2-[bis(2-hydroxyethyl)amino]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-ethoxyphenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OCC)=CC=1C=C1SC(N(CCO)CCO)=NC1=O FNORKXYVHGIFEP-UHFFFAOYSA-N 0.000 description 1
• CWDHNITZQNNCGN-UHFFFAOYSA-N 4-[4-[[2-[bis(2-hydroxyethyl)amino]-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-fluorophenoxy]-3-(trifluoromethyl)benzonitrile Chemical compound S1C(N(CCO)CCO)=NC(=O)C1=CC(C=C1F)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F CWDHNITZQNNCGN-UHFFFAOYSA-N 0.000 description 1
• KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
• NALVGTOMKSKFFV-UHFFFAOYSA-N 4-fluoro-3-methoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC=C1F NALVGTOMKSKFFV-UHFFFAOYSA-N 0.000 description 1
• UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
• XQSGYYNFKIQWAC-UHFFFAOYSA-N 4-fluoronaphthalene-1-carbonitrile Chemical compound C1=CC=C2C(F)=CC=C(C#N)C2=C1 XQSGYYNFKIQWAC-UHFFFAOYSA-N 0.000 description 1
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
• GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
• NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 1
• FZZFQQOZQKWQKG-UHFFFAOYSA-N 5-[3-(4-ethylphenoxy)propyl]-1h-imidazole Chemical compound C1=CC(CC)=CC=C1OCCCC1=CNC=N1 FZZFQQOZQKWQKG-UHFFFAOYSA-N 0.000 description 1
• GLSKFZAVXLRZDH-UHFFFAOYSA-N 5-[3-[3-(4-chlorophenyl)propoxy]propyl]-1h-imidazole Chemical compound C1=CC(Cl)=CC=C1CCCOCCCC1=CN=CN1 GLSKFZAVXLRZDH-UHFFFAOYSA-N 0.000 description 1
• ZAGFXUMBSUVWFZ-UHFFFAOYSA-N 5-[3-[4-(trifluoromethyl)phenoxy]propyl]-1h-imidazole Chemical compound C1=CC(C(F)(F)F)=CC=C1OCCCC1=CNC=N1 ZAGFXUMBSUVWFZ-UHFFFAOYSA-N 0.000 description 1
• XWAVMAGEDNCGMV-UHFFFAOYSA-N 5-[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]-3-methyl-1,3-thiazolidine-2,4-dione Chemical compound O=C1N(C)C(=O)SC1C1=CC=C(C=C(OCC=2C(=CC=CC=2)F)C=C2)C2=C1 XWAVMAGEDNCGMV-UHFFFAOYSA-N 0.000 description 1
• VFDUEWXGXROOAO-UHFFFAOYSA-N 5-[[4-[(6-methoxy-1H-benzimidazol-2-yl)methoxy]phenyl]methyl]-4,5-dihydro-1,3-thiazole Chemical compound COC1=CC2=C(NC(=N2)COC2=CC=C(CC3CN=CS3)C=C2)C=C1 VFDUEWXGXROOAO-UHFFFAOYSA-N 0.000 description 1
• CKUIKDHCECGKHI-UHFFFAOYSA-N 5-[[4-[2,4-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-2-(3-oxopiperazin-1-yl)-1,3-thiazol-4-one Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C(F)(F)F)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCNC(=O)C1 CKUIKDHCECGKHI-UHFFFAOYSA-N 0.000 description 1
• YVQKIDLSVHRBGZ-UHFFFAOYSA-N 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1C(O)COC(C=C1)=CC=C1CC1SC(=O)NC1=O YVQKIDLSVHRBGZ-UHFFFAOYSA-N 0.000 description 1
• DPCWGNQOKPHYLQ-UHFFFAOYSA-N 5-[[4-[4-chloro-2-(trifluoromethyl)phenoxy]-3-fluorophenyl]methylidene]-2-[3-(2-oxopyrrolidin-1-yl)propylamino]-1,3-thiazol-4-one Chemical compound C=1C=C(OC=2C(=CC(Cl)=CC=2)C(F)(F)F)C(F)=CC=1C=C(C(N=1)=O)SC=1NCCCN1CCCC1=O DPCWGNQOKPHYLQ-UHFFFAOYSA-N 0.000 description 1
• HTIOZYSUZOLCDN-UHFFFAOYSA-N 5-[[4-[4-chloro-2-(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-2-(3-oxopiperazin-1-yl)-1,3-thiazol-4-one Chemical compound C=1C=C(OC=2C(=CC(Cl)=CC=2)C(F)(F)F)C(OC)=CC=1C=C(C(N=1)=O)SC=1N1CCNC(=O)C1 HTIOZYSUZOLCDN-UHFFFAOYSA-N 0.000 description 1
• HREUGOAZLRNTEM-UHFFFAOYSA-N 5-benzyl-1h-imidazole Chemical compound C=1C=CC=CC=1CC1=CN=CN1 HREUGOAZLRNTEM-UHFFFAOYSA-N 0.000 description 1
• IKBZAUYPBWFMDI-UHFFFAOYSA-N 5-bromo-4-methoxy-7-methyl-2,3-dihydro-1h-indene Chemical compound C1=C(Br)C(OC)=C2CCCC2=C1C IKBZAUYPBWFMDI-UHFFFAOYSA-N 0.000 description 1
• XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
• VNACOBVZDCLAEV-UHFFFAOYSA-N 6-[2-[[2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile;dihydrochloride Chemical compound Cl.Cl.C1CCC(C#N)N1C(=O)CNCCNC1=CC=C(C#N)C=N1 VNACOBVZDCLAEV-UHFFFAOYSA-N 0.000 description 1
• DDSBPUYZPWNNGH-UHFFFAOYSA-N 6-n-[(4-nitrophenyl)methyl]-2-n-[[3-(trifluoromethyl)phenyl]methyl]-7h-purine-2,6-diamine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CNC1=NC(NCC=2C=C(C=CC=2)C(F)(F)F)=NC2=C1NC=N2 DDSBPUYZPWNNGH-UHFFFAOYSA-N 0.000 description 1
• GGDBEAVVGFNWIA-UHFFFAOYSA-N 6-nitro-2-(1-piperazinyl)quinoline Chemical class C1=CC2=CC([N+](=O)[O-])=CC=C2N=C1N1CCNCC1 GGDBEAVVGFNWIA-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• IRZGZIBVTLESAX-UHFFFAOYSA-N 7-[4-[(3,4-difluorobenzoyl)carbamothioyl]piperazin-1-yl]-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N(CC1)CCN1C(=S)NC(=O)C1=CC=C(F)C(F)=C1 IRZGZIBVTLESAX-UHFFFAOYSA-N 0.000 description 1
• CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
• NOTFORJMJSKOFQ-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane-4-carboxylic acid Chemical compound OC(=O)C1CCC2CCC1N2 NOTFORJMJSKOFQ-UHFFFAOYSA-N 0.000 description 1
• GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
• ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 108010013043 Acetylesterase Proteins 0.000 description 1
• 229910002012 Aerosil® Inorganic materials 0.000 description 1
• 101710145634 Antigen 1 Proteins 0.000 description 1
• 102000014654 Aromatase Human genes 0.000 description 1
• 108010078554 Aromatase Proteins 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
• 102100034159 Beta-3 adrenergic receptor Human genes 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 102000013585 Bombesin Human genes 0.000 description 1
• 108010051479 Bombesin Proteins 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• HEYVINCGKDONRU-UHFFFAOYSA-N Bupropion hydrochloride Chemical compound Cl.CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 HEYVINCGKDONRU-UHFFFAOYSA-N 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 239000002083 C09CA01 - Losartan Substances 0.000 description 1
• 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
• ZGCYMNJHHKQEGA-KPYOPSEVSA-N C1([C@@H]2[C@@H]([C@H]3CC[C@@H](C2)N3C)C=2ON=C(C=2)C=2C=CC=CC=2)=CC=C(Cl)C=C1 Chemical compound C1([C@@H]2[C@@H]([C@H]3CC[C@@H](C2)N3C)C=2ON=C(C=2)C=2C=CC=CC=2)=CC=C(Cl)C=C1 ZGCYMNJHHKQEGA-KPYOPSEVSA-N 0.000 description 1
• DDYJDIHOSRTMSE-FLIBITNWSA-N CGP 52608 Chemical compound CNC(=S)N\N=C1/SCC(=O)N1CC=C DDYJDIHOSRTMSE-FLIBITNWSA-N 0.000 description 1
• PHKYGBHARUTZOY-UHFFFAOYSA-N CKD-711 Natural products OC1C(O)C(NC2C(C(O)C(O)C3(CO)OC32)O)C(CO)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O PHKYGBHARUTZOY-UHFFFAOYSA-N 0.000 description 1
• 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
• 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 229920013683 Celanese Polymers 0.000 description 1
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
• 241000251477 Chimaera Species 0.000 description 1
• 241001227713 Chiron Species 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 101800001982 Cholecystokinin Proteins 0.000 description 1
• 102100025841 Cholecystokinin Human genes 0.000 description 1
• 102100035932 Cocaine- and amphetamine-regulated transcript protein Human genes 0.000 description 1
• 229920002911 Colestipol Polymers 0.000 description 1
• 102100021752 Corticoliberin Human genes 0.000 description 1
• 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
• GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 238000000018 DNA microarray Methods 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• 208000030814 Eating disease Diseases 0.000 description 1
• 108010066671 Enalaprilat Proteins 0.000 description 1
• 239000004593 Epoxy Substances 0.000 description 1
• 102100038595 Estrogen receptor Human genes 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
• 108010027279 Facilitative Glucose Transport Proteins Proteins 0.000 description 1
• 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
• 229940123469 Fatty acid synthase inhibitor Drugs 0.000 description 1
• 101710118908 Fatty acid-binding protein, adipocyte Proteins 0.000 description 1
• 208000019454 Feeding and Eating disease Diseases 0.000 description 1
• 241000722985 Fidia Species 0.000 description 1
• 102100023374 Forkhead box protein M1 Human genes 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
• 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 1
• 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
• 108010002894 GW 1229 Proteins 0.000 description 1
• 229940121970 Galanin receptor antagonist Drugs 0.000 description 1
• HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
• 102000051325 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• 101800001754 Glucagon-like peptide 1-1 Proteins 0.000 description 1
• 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
• 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
• 101710185468 Glutamine-fructose-6-phosphate aminotransferase [isomerizing] Proteins 0.000 description 1
• 102100033429 Glutamine-fructose-6-phosphate aminotransferase [isomerizing] 1 Human genes 0.000 description 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
• 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 239000007821 HATU Substances 0.000 description 1
• 108010024770 HP 228 Proteins 0.000 description 1
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
• HAPWZEVRQYGLSG-IUCAKERBSA-N His-Gly-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O HAPWZEVRQYGLSG-IUCAKERBSA-N 0.000 description 1
• STGQSBKUYSPPIG-CIUDSAMLSA-N His-Ser-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 STGQSBKUYSPPIG-CIUDSAMLSA-N 0.000 description 1
• 229940115480 Histamine H3 receptor antagonist Drugs 0.000 description 1
• 102000006947 Histones Human genes 0.000 description 1
• 101000715592 Homo sapiens Cocaine- and amphetamine-regulated transcript protein Proteins 0.000 description 1
• 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
• 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 1
• 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
• 108010084048 Human Isophane Insulin Proteins 0.000 description 1
• 102000005561 Human Isophane Insulin Human genes 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• AKOAEVOSDHIVFX-UHFFFAOYSA-N Hydroxybupropion Chemical compound OCC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 AKOAEVOSDHIVFX-UHFFFAOYSA-N 0.000 description 1
• 102000001284 I-kappa-B kinase Human genes 0.000 description 1
• 108060006678 I-kappa-B kinase Proteins 0.000 description 1
• 229940122355 Insulin sensitizer Drugs 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
• CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 229940086609 Lipase inhibitor Drugs 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 229940124757 MC-4 agonist Drugs 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
• 102000004378 Melanocortin Receptors Human genes 0.000 description 1
• 108090000950 Melanocortin Receptors Proteins 0.000 description 1
• 108010008364 Melanocortins Proteins 0.000 description 1
• 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
• 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
• 101710200814 Melanotropin alpha Proteins 0.000 description 1
• 101710201349 Metallothionein B Proteins 0.000 description 1
• 102100031347 Metallothionein-2 Human genes 0.000 description 1
• 101710094505 Metallothionein-2 Proteins 0.000 description 1
• RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 description 1
• 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 1
• 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 1
• 101001095964 Mus musculus Patatin-like phospholipase domain-containing protein 7 Proteins 0.000 description 1
• AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
• KHCFKCPXXJQHMH-UHFFFAOYSA-N N-[5-[5-chloro-2-(difluoromethoxy)phenyl]-1H-pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C1=NNC=C1NC(=O)C=1C=NN2C1N=CC=C2)OC(F)F KHCFKCPXXJQHMH-UHFFFAOYSA-N 0.000 description 1
• GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical compound N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 description 1
• XTLFOGNEQSPWGW-SFHVURJKSA-N N6-myristoyl lysine Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@H](N)C(O)=O XTLFOGNEQSPWGW-SFHVURJKSA-N 0.000 description 1
• 229940123247 Neurotransmitter antagonist Drugs 0.000 description 1
• ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
• 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 1
• 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 108010047956 Nucleosomes Proteins 0.000 description 1
• REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 description 1
• 102000004316 Oxidoreductases Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• 102000017946 PGC-1 Human genes 0.000 description 1
• 108700038399 PGC-1 Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241000282320 Panthera leo Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
• 229940084820 Peroxisome proliferator-activated receptor alpha agonist Drugs 0.000 description 1
• 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 229920001219 Polysorbate 40 Polymers 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• 108010005991 Pork Regular Insulin Proteins 0.000 description 1
• 229940122117 Potassium channel agonist Drugs 0.000 description 1
• 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
• 101710176049 Probable glutamine-fructose-6-phosphate aminotransferase [isomerizing] Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 101710198235 Putative glutamine-fructose-6-phosphate aminotransferase [isomerizing] Proteins 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 108010021820 SHU 9119 Proteins 0.000 description 1
• 108091006300 SLC2A4 Proteins 0.000 description 1
• 239000004113 Sepiolite Substances 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• 229940122490 Sigma receptor antagonist Drugs 0.000 description 1
• BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 241001455617 Sula Species 0.000 description 1
• 229940100389 Sulfonylurea Drugs 0.000 description 1
• CHBGBJNXHMNLOQ-UHFFFAOYSA-N TAN-1612 Chemical class COc1cc(O)c2c(O)c3C(=O)C4(O)C(=O)C(=C(O)CC4(O)Cc3cc2c1)C(=O)C CHBGBJNXHMNLOQ-UHFFFAOYSA-N 0.000 description 1
• 239000012317 TBTU Substances 0.000 description 1
• ODKDMMTXTVCCLJ-UHFFFAOYSA-N TMC-2A Natural products C1=CC=C2C(CC(N)C(=O)N3C(CC4=CC(O)=C(C(=C4C3)O)OC)C(=O)NC(CC(CO)CO)C(O)=O)=CNC2=C1 ODKDMMTXTVCCLJ-UHFFFAOYSA-N 0.000 description 1
• WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
• VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
• 102000008817 Trefoil Factor-1 Human genes 0.000 description 1
• 108010088412 Trefoil Factor-1 Proteins 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• 244000098338 Triticum aestivum Species 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 1
• 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
• 102000005630 Urocortins Human genes 0.000 description 1
• 108010059705 Urocortins Proteins 0.000 description 1
• 108010078660 Vaseretic Proteins 0.000 description 1
• MFMMJKGZEGTTSV-UHFFFAOYSA-N Verongamine Natural products C1=C(Br)C(OC)=CC=C1CC(=NO)C(=O)NCCC1=CN=CN1 MFMMJKGZEGTTSV-UHFFFAOYSA-N 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 241000079527 Ziziphus spina-christi Species 0.000 description 1
• GKDKOMAJZATYAY-GCVPSNMTSA-N [(1r,2s,4r,5r)-2,3,4-trihydroxy-5,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1O GKDKOMAJZATYAY-GCVPSNMTSA-N 0.000 description 1
• UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 description 1
• CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
• 229940077422 accupril Drugs 0.000 description 1
• GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 229940062328 actos Drugs 0.000 description 1
• 229940092980 adalat Drugs 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 230000011759 adipose tissue development Effects 0.000 description 1
• 230000001800 adrenalinergic effect Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• XCSGPAVHZFQHGE-UHFFFAOYSA-N alachlor Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl XCSGPAVHZFQHGE-UHFFFAOYSA-N 0.000 description 1
• GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 150000001335 aliphatic alkanes Chemical class 0.000 description 1
• 229960001445 alitretinoin Drugs 0.000 description 1
• 150000001345 alkine derivatives Chemical class 0.000 description 1
• 239000002160 alpha blocker Substances 0.000 description 1
• AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 229940077927 altace Drugs 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 239000003392 amylase inhibitor Substances 0.000 description 1
• 239000003263 anabolic agent Substances 0.000 description 1
• 229940070021 anabolic steroids Drugs 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 230000003127 anti-melanomic effect Effects 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940030600 antihypertensive agent Drugs 0.000 description 1
• 229940124693 antiobesity therapeutics Drugs 0.000 description 1
• VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
• 229960004046 apomorphine Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 229960005261 aspartic acid Drugs 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 229940058087 atacand Drugs 0.000 description 1
• METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
• 229960002430 atomoxetine Drugs 0.000 description 1
• FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
• 229960000892 attapulgite Drugs 0.000 description 1
• 229940090047 auto-injector Drugs 0.000 description 1
• 229940062310 avandia Drugs 0.000 description 1
• 229940000201 avapro Drugs 0.000 description 1
• 229940072293 axid Drugs 0.000 description 1
• 108010014210 axokine Proteins 0.000 description 1
• XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• 150000003935 benzaldehydes Chemical class 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• 150000001556 benzimidazoles Chemical class 0.000 description 1
• YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
• 229960002837 benzphetamine Drugs 0.000 description 1
• 150000003939 benzylamines Chemical class 0.000 description 1
• UEECHQPWQHYEDE-UHFFFAOYSA-N bepridil hydrochloride monohydrate Chemical compound [H+].O.[Cl-].C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UEECHQPWQHYEDE-UHFFFAOYSA-N 0.000 description 1
• BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 1
• 108040005346 beta3-adrenergic receptor activity proteins Proteins 0.000 description 1
• 229940099231 betapace Drugs 0.000 description 1
• CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
• KUWBXRGRMQZCSS-HSZRJFAPSA-N bibp-3226 Chemical compound N([C@H](CCCN=C(N)N)C(=O)NCC=1C=CC(O)=CC=1)C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 KUWBXRGRMQZCSS-HSZRJFAPSA-N 0.000 description 1
• RSJAXPUYVJKAAA-JPGJPTAESA-N biie-0246 Chemical compound N([C@@H](CCCN=C(N)N)C(=O)NCCN1C(N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C1=O)=O)C(=O)CC1(CC(=O)N2CCN(CC2)C2C3=CC=CC=C3C(=O)NC3=CC=CC=C32)CCCC1 RSJAXPUYVJKAAA-JPGJPTAESA-N 0.000 description 1
• 229920000080 bile acid sequestrant Polymers 0.000 description 1
• 229940096699 bile acid sequestrants Drugs 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000008436 biogenesis Effects 0.000 description 1
• SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
• VMDFASMUILANOL-WXXKFALUSA-N bisoprolol fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VMDFASMUILANOL-WXXKFALUSA-N 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000037182 bone density Effects 0.000 description 1
• 230000014461 bone development Effects 0.000 description 1
• 210000002805 bone matrix Anatomy 0.000 description 1
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
• 239000004327 boric acid Substances 0.000 description 1
• 229940097683 brevibloc Drugs 0.000 description 1
• OLQJWCYRPYGTJI-UHFFFAOYSA-N bts 74,398 Chemical compound C=1C=C(Cl)C(Cl)=CC=1C1(C(=O)CSCCCN(CCN)CCN)CCC1 OLQJWCYRPYGTJI-UHFFFAOYSA-N 0.000 description 1
• 229960004367 bupropion hydrochloride Drugs 0.000 description 1
• 125000005510 but-1-en-2-yl group Chemical group 0.000 description 1
• 125000005514 but-1-yn-3-yl group Chemical group 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 229940088033 calan Drugs 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
• UBWYRXFZPXBISJ-UHFFFAOYSA-L calcium;2-hydroxypropanoate;trihydrate Chemical compound O.O.O.[Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O UBWYRXFZPXBISJ-UHFFFAOYSA-L 0.000 description 1
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
• 229960000830 captopril Drugs 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 229960001631 carbomer Drugs 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 229940096529 carboxypolymethylene Drugs 0.000 description 1
• 229940097611 cardene Drugs 0.000 description 1
• 229940088029 cardizem Drugs 0.000 description 1
• 229940072282 cardura Drugs 0.000 description 1
• 239000004203 carnauba wax Substances 0.000 description 1
• 235000013869 carnauba wax Nutrition 0.000 description 1
• FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 description 1
• OGHNVEJMJSYVRP-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2 OGHNVEJMJSYVRP-UHFFFAOYSA-N 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 229940047493 celexa Drugs 0.000 description 1
• 230000011748 cell maturation Effects 0.000 description 1
• 241000902900 cellular organisms Species 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
• 229950000303 cericlamine Drugs 0.000 description 1
• MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
• 229950002397 cetilistat Drugs 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• UULIGRNKXHCLQN-WGSAOQKQSA-N chembl17645 Chemical compound C1=CC=C2C(N)=NC(NC[C@@H]3CC[C@@H](CNS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)CC3)=NC2=C1 UULIGRNKXHCLQN-WGSAOQKQSA-N 0.000 description 1
• ZWGWSFHAZWNQQE-VPLSKCCHSA-N chembl1836102 Chemical compound Cl.C1=CC=C2C(N)=NC(NC[C@@H]3CC[C@@H](CNS(=O)(=O)C=4C=C5C=CC=CC5=CC=4)CC3)=NC2=C1 ZWGWSFHAZWNQQE-VPLSKCCHSA-N 0.000 description 1
• RJRBRCCJETZJLT-FDYNHNOGSA-N chembl2110365 Chemical compound C([C@H](NC(=O)[C@@H]1CNC(=O)CC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CNC(=O)CC[C@@H](C(N2CCC[C@H]2C(=O)N1)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 RJRBRCCJETZJLT-FDYNHNOGSA-N 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
• 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• 229940107137 cholecystokinin Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 230000001886 ciliary effect Effects 0.000 description 1
• PHKYGBHARUTZOY-KTVVNDHVSA-N ckd-711 Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@]2(CO)O[C@@H]21)O)CO)[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O PHKYGBHARUTZOY-KTVVNDHVSA-N 0.000 description 1
• KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 229940097479 colestid Drugs 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 230000008876 conformational transition Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 229940069210 coreg Drugs 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 229940097499 cozaar Drugs 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 150000001924 cycloalkanes Chemical class 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• LQNHRNOPWKZUSN-UHFFFAOYSA-N cyclobutylmethanamine Chemical compound NCC1CCC1 LQNHRNOPWKZUSN-UHFFFAOYSA-N 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
• GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 229940087490 dibenzyline Drugs 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• 229960004890 diethylpropion Drugs 0.000 description 1
• XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
• 229940044369 dilacor Drugs 0.000 description 1
• 229940064420 dilatrate Drugs 0.000 description 1
• 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
• 229940074619 diovan Drugs 0.000 description 1
• 235000014632 disordered eating Nutrition 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
• 229960003638 dopamine Drugs 0.000 description 1
• 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000007908 dry granulation Methods 0.000 description 1
• 229940112141 dry powder inhaler Drugs 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 229950000269 emiglitate Drugs 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 210000001163 endosome Anatomy 0.000 description 1
• 230000037149 energy metabolism Effects 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 229960002179 ephedrine Drugs 0.000 description 1
• AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
• 102000015694 estrogen receptors Human genes 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 108010015174 exendin 3 Proteins 0.000 description 1
• LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 1
• 229950003707 farglitazar Drugs 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 108091022862 fatty acid binding Proteins 0.000 description 1
• 150000002194 fatty esters Chemical class 0.000 description 1
• RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
• 229960002297 fenofibrate Drugs 0.000 description 1
• 230000035558 fertility Effects 0.000 description 1
• 239000007888 film coating Substances 0.000 description 1
• 238000009501 film coating Methods 0.000 description 1
• 238000001007 flame atomic emission spectroscopy Methods 0.000 description 1
• 239000012054 flavored emulsion Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 235000020375 flavoured syrup Nutrition 0.000 description 1
• VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 description 1
• 229960002107 fluvoxamine maleate Drugs 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 108010084802 galparan Proteins 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• 239000003850 glucocorticoid receptor antagonist Substances 0.000 description 1
• 229940124828 glucokinase activator Drugs 0.000 description 1
• 230000004110 gluconeogenesis Effects 0.000 description 1
• 229940095884 glucophage Drugs 0.000 description 1
• 229960001031 glucose Drugs 0.000 description 1
• 230000009229 glucose formation Effects 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 108010085742 growth hormone-releasing peptide-2 Proteins 0.000 description 1
• 229960003845 guanadrel Drugs 0.000 description 1
• RTEVGQJRTFFMLL-UHFFFAOYSA-N guanadrel sulfate Chemical compound OS(O)(=O)=O.O1C(CN=C(N)N)COC11CCCCC1.O1C(CN=C(N)N)COC11CCCCC1 RTEVGQJRTFFMLL-UHFFFAOYSA-N 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
• 229910000271 hectorite Inorganic materials 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 108010045383 histidyl-glycyl-glutamic acid Proteins 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229940038661 humalog Drugs 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
• 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
• 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
• 229940093221 imdur Drugs 0.000 description 1
• 150000002460 imidazoles Chemical class 0.000 description 1
• TWWVIHLFNDYKFN-UHFFFAOYSA-N imidazolidine;morpholine Chemical compound C1CNCN1.C1COCCN1 TWWVIHLFNDYKFN-UHFFFAOYSA-N 0.000 description 1
• MZCJWLAXZRFUPI-UHFFFAOYSA-N impentamine Chemical compound NCCCCCC1=CN=CN1 MZCJWLAXZRFUPI-UHFFFAOYSA-N 0.000 description 1
• 229940095990 inderal Drugs 0.000 description 1
• 230000000053 inderal effect Effects 0.000 description 1
• 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
• HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 229960000367 inositol Drugs 0.000 description 1
• 229960004717 insulin aspart Drugs 0.000 description 1
• 229960003948 insulin detemir Drugs 0.000 description 1
• 229960002869 insulin glargine Drugs 0.000 description 1
• 229960002068 insulin lispro Drugs 0.000 description 1
• 230000003914 insulin secretion Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• YOSHYTLCDANDAN-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2NN=NN=2)C(CCCC)=NC21CCCC2 YOSHYTLCDANDAN-UHFFFAOYSA-N 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 229940072673 ismo Drugs 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
• 229940088024 isoptin Drugs 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• 229940090473 januvia Drugs 0.000 description 1
• 229940072289 kerlone Drugs 0.000 description 1
• RJRBRCCJETZJLT-UHFFFAOYSA-N l024001 Chemical compound N1C(=O)C2CCCN2C(=O)C(NC(=O)C(N)C(C)CC)CCC(=O)NCC(C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=2C=CC(O)=CC=2)C(N)=O)NC(=O)C2CCCN2C(=O)C(NC(=O)C(N)C(C)CC)CCC(=O)NCC1C(=O)NC(C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=1C=CC(O)=CC=1)C(N)=O)CC1=CC=C(O)C=C1 RJRBRCCJETZJLT-UHFFFAOYSA-N 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229940060975 lantus Drugs 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 102000005861 leptin receptors Human genes 0.000 description 1
• 108010019813 leptin receptors Proteins 0.000 description 1
• 229940095570 lescol Drugs 0.000 description 1
• 229940080157 lexxel Drugs 0.000 description 1
• QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 125000005647 linker group Chemical group 0.000 description 1
• 230000037356 lipid metabolism Effects 0.000 description 1
• 229940002661 lipitor Drugs 0.000 description 1
• 108010033243 lisinopril drug combination hydrochlorothiazide Proteins 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 229940063720 lopid Drugs 0.000 description 1
• 229940089504 lopressor Drugs 0.000 description 1
• PSIFNNKUMBGKDQ-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 PSIFNNKUMBGKDQ-UHFFFAOYSA-N 0.000 description 1
• 229940080268 lotensin Drugs 0.000 description 1
• 229940080266 lotensin hct Drugs 0.000 description 1
• 229940080288 lotrel Drugs 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 229940009622 luvox Drugs 0.000 description 1
• 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 229960001855 mannitol Drugs 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 229940103179 mavik Drugs 0.000 description 1
• 229960000299 mazindol Drugs 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 229950004994 meglitinide Drugs 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• 239000002865 melanocortin Substances 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
• 229960004329 metformin hydrochloride Drugs 0.000 description 1
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
• VMITZEMDDZVHBZ-XNISGKROSA-N methyl (1s,3s,4s,5r)-3-(4-chloro-3-methylphenyl)-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@H]2C(=O)OC)=CC=C(Cl)C(C)=C1 VMITZEMDDZVHBZ-XNISGKROSA-N 0.000 description 1
• IVAQJHSXBVHUQT-ZVHZXABRSA-N methyl (e)-3-(3,5-dimethoxyphenyl)-2-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]prop-2-enoate Chemical compound C=1C=C(OC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)C=CC=1/C(C(=O)OC)=C\C1=CC(OC)=CC(OC)=C1 IVAQJHSXBVHUQT-ZVHZXABRSA-N 0.000 description 1
• FUKCWBLTTXRNAC-UHFFFAOYSA-N methyl 1-[5-[[4-[4-cyano-2-(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C(S1)=NC(=O)C1=CC(C=C1OC)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F FUKCWBLTTXRNAC-UHFFFAOYSA-N 0.000 description 1
• OABFXHWLMASPHY-UHFFFAOYSA-N methyl 2-[[5-[[4-[4-cyano-2-(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]amino]-3-hydroxypropanoate Chemical compound S1C(NC(CO)C(=O)OC)=NC(=O)C1=CC(C=C1OC)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F OABFXHWLMASPHY-UHFFFAOYSA-N 0.000 description 1
• LZGDMYCYJCDCLT-UHFFFAOYSA-N methyl 2-[[5-[[4-[4-cyano-2-(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]amino]acetate Chemical compound S1C(NCC(=O)OC)=NC(=O)C1=CC(C=C1OC)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F LZGDMYCYJCDCLT-UHFFFAOYSA-N 0.000 description 1
• YOGRJAGBRRCAGX-UHFFFAOYSA-N methyl 4-[4-[[2-(3-hydroxypiperidin-1-yl)-4-oxo-1,3-thiazol-5-ylidene]methyl]-2-methoxyphenoxy]-3-(trifluoromethyl)benzoate Chemical compound FC(F)(F)C1=CC(C(=O)OC)=CC=C1OC(C(=C1)OC)=CC=C1C=C1C(=O)N=C(N2CC(O)CCC2)S1 YOGRJAGBRRCAGX-UHFFFAOYSA-N 0.000 description 1
• YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
• 150000004702 methyl esters Chemical class 0.000 description 1
• LUCXVPAZUDVVBT-UHFFFAOYSA-N methyl-[3-(2-methylphenoxy)-3-phenylpropyl]azanium;chloride Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1C LUCXVPAZUDVVBT-UHFFFAOYSA-N 0.000 description 1
• GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
• 229940099246 mevacor Drugs 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 229940064639 minipress Drugs 0.000 description 1
• 229940101635 minizide Drugs 0.000 description 1
• 231100001056 minor skeletal defect Toxicity 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 229940063181 monoket Drugs 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 229940118178 monopril Drugs 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 1
• OGVGPAOFGPGDKJ-UHFFFAOYSA-N n-[1-(furan-2-ylmethyl)-5-oxo-2-phenyl-4-(trifluoromethyl)imidazol-4-yl]thiophene-2-carboxamide Chemical compound N1=C(C=2C=CC=CC=2)N(CC=2OC=CC=2)C(=O)C1(C(F)(F)F)NC(=O)C1=CC=CS1 OGVGPAOFGPGDKJ-UHFFFAOYSA-N 0.000 description 1
• XEQICFAPISGJTR-UHFFFAOYSA-N n-cyclohexyl-1h-indol-2-amine Chemical class C1CCCCC1NC1=CC2=CC=CC=C2N1 XEQICFAPISGJTR-UHFFFAOYSA-N 0.000 description 1
• NDVZIUGCCMZHLG-UHFFFAOYSA-N n-methyl-3-(2-methylsulfanylphenoxy)-3-phenylpropan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1SC NDVZIUGCCMZHLG-UHFFFAOYSA-N 0.000 description 1
• GWCQNKRMTGVYIZ-UHFFFAOYSA-N n-naphthalen-1-yl-1-pentylindole-3-carboxamide Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)NC1=CC=CC2=CC=CC=C12 GWCQNKRMTGVYIZ-UHFFFAOYSA-N 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 229920001206 natural gum Polymers 0.000 description 1
• 229920005615 natural polymer Polymers 0.000 description 1
• 229960001800 nefazodone Drugs 0.000 description 1
• 239000002658 neuropeptide Y receptor agonist Substances 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• UIAGMCDKSXEBJQ-UHFFFAOYSA-N nimodipine Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-UHFFFAOYSA-N 0.000 description 1
• 229940072101 nimotop Drugs 0.000 description 1
• 150000002825 nitriles Chemical class 0.000 description 1
• 229940072991 nitro-bid Drugs 0.000 description 1
• 229940072981 nitro-dur Drugs 0.000 description 1
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 229940073015 nitrostat Drugs 0.000 description 1
• 229960004872 nizatidine Drugs 0.000 description 1
• 229940073555 nonoxynol-10 Drugs 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 229940112879 novolog Drugs 0.000 description 1
• VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 1
• 210000001623 nucleosome Anatomy 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• BWRRXOIACQYNEK-UHFFFAOYSA-N o-[2-(1,3-dioxo-1,3-dihydro-2h-isoindol-2-yl)ethyl] (4-chlorophenyl)thiocarbamate Chemical compound C1=CC(Cl)=CC=C1NC(=S)OCCN1C(=O)C2=CC=CC=C2C1=O BWRRXOIACQYNEK-UHFFFAOYSA-N 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 229940098514 octoxynol-9 Drugs 0.000 description 1
• 229920002114 octoxynol-9 Polymers 0.000 description 1
• 239000012053 oil suspension Substances 0.000 description 1
• FAHGZANUNVVDFL-HYBUGGRVSA-N omiloxetine Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](COC=2C=C3OCOC3=CC=2)CN(CC(=O)C=2C=CC(F)=CC=2)CC1 FAHGZANUNVVDFL-HYBUGGRVSA-N 0.000 description 1
• 229950005637 omiloxetine Drugs 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 239000012044 organic layer Substances 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 102000004164 orphan nuclear receptors Human genes 0.000 description 1
• 108090000629 orphan nuclear receptors Proteins 0.000 description 1
• 230000004072 osteoblast differentiation Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
• 229960000464 oxandrolone Drugs 0.000 description 1
• 150000002923 oximes Chemical class 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
• 239000006174 pH buffer Substances 0.000 description 1
• 235000019629 palatability Nutrition 0.000 description 1
• 229910052625 palygorskite Inorganic materials 0.000 description 1
• 239000003182 parenteral nutrition solution Substances 0.000 description 1
• 239000004031 partial agonist Substances 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 229960000292 pectin Drugs 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 229960003209 phenmetrazine Drugs 0.000 description 1
• KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical class O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 description 1
• 125000005359 phenoxyalkyl group Chemical group 0.000 description 1
• UVNAYBAOZUMARC-TVEJVZOKSA-N phenyl (1s,3s,4s,5r)-3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate;hydrochloride Chemical compound Cl.C1([C@@H]2[C@@H]([C@]3(CC[C@@](C2)(N3C)[H])[H])C(=O)OC=2C=CC=CC=2)=CC=C(Cl)C=C1 UVNAYBAOZUMARC-TVEJVZOKSA-N 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
• 229960000395 phenylpropanolamine Drugs 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000008105 phosphatidylcholines Chemical class 0.000 description 1
• 229930004090 phosphatidylinositide Natural products 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
• 229960002827 pioglitazone hydrochloride Drugs 0.000 description 1
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
• RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
• 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 229940090013 plendil Drugs 0.000 description 1
• 229920000867 polyelectrolyte Polymers 0.000 description 1
• 229920000193 polymethacrylate Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
• 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 229940068977 polysorbate 20 Drugs 0.000 description 1
• 229940101027 polysorbate 40 Drugs 0.000 description 1
• 229940113124 polysorbate 60 Drugs 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
• 230000000291 postprandial effect Effects 0.000 description 1
• 235000011181 potassium carbonates Nutrition 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 229960002847 prasterone Drugs 0.000 description 1
• 229940089484 pravachol Drugs 0.000 description 1
• VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
• WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
• 229940095885 precose Drugs 0.000 description 1
• GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
• 229940088953 prinivil Drugs 0.000 description 1
• 229940117265 prinzide Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 229940089949 procardia Drugs 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 108010070701 procolipase Proteins 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 108010031719 prolyl-serine Proteins 0.000 description 1
• 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 1
• AGWBYBRETVEPSZ-UHFFFAOYSA-N prop-2-enyl n-[3-[[[6-[(5-ethyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-4-morpholin-4-ylpyridin-2-yl]amino]methyl]phenyl]carbamate Chemical compound S1C(CC)=NN=C1SCC1=CC(N2CCOCC2)=CC(NCC=2C=C(NC(=O)OCC=C)C=CC=2)=N1 AGWBYBRETVEPSZ-UHFFFAOYSA-N 0.000 description 1
• JNFARUXJNLDBCZ-UHFFFAOYSA-N prop-2-enyl n-[3-[[[6-[(5-ethyl-1,3-thiazol-2-yl)sulfanylmethyl]-4-morpholin-4-ylpyridin-2-yl]amino]methyl]-5-methoxyphenyl]carbamate Chemical compound S1C(CC)=CN=C1SCC1=CC(N2CCOCC2)=CC(NCC=2C=C(OC)C=C(NC(=O)OCC=C)C=2)=N1 JNFARUXJNLDBCZ-UHFFFAOYSA-N 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 230000009979 protective mechanism Effects 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 150000003217 pyrazoles Chemical class 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
• ALSCEGDXFJIYES-UHFFFAOYSA-N pyrrolidine-2-carbonitrile Chemical compound N#CC1CCCN1 ALSCEGDXFJIYES-UHFFFAOYSA-N 0.000 description 1
• 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
• 229940073095 questran Drugs 0.000 description 1
• IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 108091006082 receptor inhibitors Proteins 0.000 description 1
• 238000004064 recycling Methods 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000000979 retarding effect Effects 0.000 description 1
• 229950006433 risarestat Drugs 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• 229960003271 rosiglitazone maleate Drugs 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 229940100992 sarafem Drugs 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 238000002805 secondary assay Methods 0.000 description 1
• 229940082552 sectral Drugs 0.000 description 1
• 235000019355 sepiolite Nutrition 0.000 description 1
• 229910052624 sepiolite Inorganic materials 0.000 description 1
• 229940099190 serzone Drugs 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 229960005303 sibutramine hydrochloride monohydrate Drugs 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 238000010898 silica gel chromatography Methods 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
• 229960004034 sitagliptin Drugs 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000000344 soap Substances 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 229960002920 sorbitol Drugs 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 229940093252 sorbitrate Drugs 0.000 description 1
• ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 229940102548 stearalkonium hectorite Drugs 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000003270 steroid hormone Substances 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000007939 sustained release tablet Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical class C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229940001587 tarka Drugs 0.000 description 1
• 229940108485 tenormin Drugs 0.000 description 1
• NZMOFYDMGFQZLS-UHFFFAOYSA-N terazosin hydrochloride dihydrate Chemical compound [H+].O.O.[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 NZMOFYDMGFQZLS-UHFFFAOYSA-N 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• JDDPITNKUXPLSB-UHFFFAOYSA-N tert-butyl morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOCC1 JDDPITNKUXPLSB-UHFFFAOYSA-N 0.000 description 1
• AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
• YSEDIEFTKVFGAP-UHFFFAOYSA-N tert-butyl n-[2-[[5-[[4-[4-cyano-2-(trifluoromethyl)phenoxy]-3-methoxyphenyl]methylidene]-4-oxo-1,3-thiazol-2-yl]amino]ethyl]carbamate Chemical compound C=1C=C(OC=2C(=CC(=CC=2)C#N)C(F)(F)F)C(OC)=CC=1C=C1SC(NCCNC(=O)OC(C)(C)C)=NC1=O YSEDIEFTKVFGAP-UHFFFAOYSA-N 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
• 150000003557 thiazoles Chemical class 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 238000004809 thin layer chromatography Methods 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 229940035248 tiazac Drugs 0.000 description 1
• ODKDMMTXTVCCLJ-BVSLBCMMSA-N tmc-2-a Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N3[C@@H](CC4=CC(O)=C(C(=C4C3)O)OC)C(=O)N[C@@H](CC(CO)CO)C(O)=O)=CNC2=C1 ODKDMMTXTVCCLJ-BVSLBCMMSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 229940110253 toujeo Drugs 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 229940108522 trandate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
• 235000011178 triphosphate Nutrition 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
• 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
• 229940054506 uniretic Drugs 0.000 description 1
• 229940054495 univasc Drugs 0.000 description 1
• 239000000777 urocortin Substances 0.000 description 1
• ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
• GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
• 229910052720 vanadium Inorganic materials 0.000 description 1
• 229940041260 vanadyl sulfate Drugs 0.000 description 1
• 229910000352 vanadyl sulfate Inorganic materials 0.000 description 1
• 229940032178 vaseretic Drugs 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 229940099270 vasotec Drugs 0.000 description 1
• 229940055010 verelan Drugs 0.000 description 1
• MFMMJKGZEGTTSV-DEDYPNTBSA-N verongamine Chemical compound C1=C(Br)C(OC)=CC=C1C\C(=N/O)C(=O)NCCC1=CNC=N1 MFMMJKGZEGTTSV-DEDYPNTBSA-N 0.000 description 1
• 229960003740 vilazodone Drugs 0.000 description 1
• SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 229940009065 wellbutrin Drugs 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• 229940002552 xenical Drugs 0.000 description 1
• 229940052204 zebeta Drugs 0.000 description 1
• 229940063159 zestoretic Drugs 0.000 description 1
• 229940072252 zestril Drugs 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 229940072168 zocor Drugs 0.000 description 1
• 229940020965 zoloft Drugs 0.000 description 1
• 229940018503 zyban Drugs 0.000 description 1